<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83159</article-id><article-id pub-id-type="doi">10.7554/eLife.83159</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>HUWE1 controls tristetraprolin proteasomal degradation by regulating its phosphorylation</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-291840"><name><surname>Scinicariello</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-291832"><name><surname>Soderholm</surname><given-names>Adrian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-291836"><name><surname>Schäfer</surname><given-names>Markus</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-291838"><name><surname>Shulkina</surname><given-names>Alexandra</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-291833"><name><surname>Schwartz</surname><given-names>Irene</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-291834"><name><surname>Hacker</surname><given-names>Kathrin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-291837"><name><surname>Gogova</surname><given-names>Rebeca</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-291835"><name><surname>Kalis</surname><given-names>Robert</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7553-4806</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-291839"><name><surname>Froussios</surname><given-names>Kimon</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2812-0525</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-291841"><name><surname>Budroni</surname><given-names>Valentina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-291842"><name><surname>Bestehorn</surname><given-names>Annika</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-52566"><name><surname>Clausen</surname><given-names>Tim</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1582-6924</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-185011"><name><surname>Kovarik</surname><given-names>Pavel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-85634"><name><surname>Zuber</surname><given-names>Johannes</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8810-6835</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-183504"><name><surname>Versteeg</surname><given-names>Gijs A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6150-2165</contrib-id><email>gijs.versteeg@univie.ac.at</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03prydq77</institution-id><institution>Department of Microbiology, Immunobiology and Genetics, Max Perutz Labs, University of Vienna, Vienna BioCenter (VBC)</institution></institution-wrap><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03prydq77</institution-id><institution>Vienna BioCenter PhD Program, Doctoral School of the University of Vienna and Medical University of Vienna, Vienna BioCenter (VBC)</institution></institution-wrap><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04khwmr87</institution-id><institution>Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC)</institution></institution-wrap><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04khwmr87</institution-id><institution>Medical University of Vienna, Vienna BioCenter (VBC)</institution></institution-wrap><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Hu</surname><given-names>Xiaoyu</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cve4549</institution-id><institution>Tsinghua University</institution></institution-wrap><country>China</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Ron</surname><given-names>David</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>University of Cambridge</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>24</day><month>03</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83159</elocation-id><history><date date-type="received" iso-8601-date="2022-09-01"><day>01</day><month>09</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-02-26"><day>26</day><month>02</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-08-29"><day>29</day><month>08</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.08.29.505645"/></event></pub-history><permissions><copyright-statement>© 2023, Scinicariello et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Scinicariello et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83159-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-83159-figures-v1.pdf"/><abstract><p>Tristetraprolin (TTP) is a critical negative immune regulator. It binds AU-rich elements in the untranslated-regions of many mRNAs encoding pro-inflammatory mediators, thereby accelerating their decay. A key but poorly understood mechanism of TTP regulation is its timely proteolytic removal: TTP is degraded by the proteasome through yet unidentified phosphorylation-controlled drivers. In this study, we set out to identify factors controlling TTP stability. Cellular assays showed that TTP is strongly lysine-ubiquitinated, which is required for its turnover. A genetic screen identified the ubiquitin E3 ligase HUWE1 as a strong regulator of TTP proteasomal degradation, which we found to control TTP stability indirectly by regulating its phosphorylation. Pharmacological assessment of multiple kinases revealed that HUWE1-regulated TTP phosphorylation and stability was independent of the previously characterized effects of MAPK-mediated S52/S178 phosphorylation. HUWE1 function was dependent on phosphatase and E3 ligase binding sites identified in the TTP C-terminus. Our findings indicate that while phosphorylation of S52/S178 is critical for TTP stabilization at earlier times after pro-inflammatory stimulation, phosphorylation of the TTP C-terminus controls its stability at later stages.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>ubiquitin</kwd><kwd>e3 ligase</kwd><kwd>huwe1</kwd><kwd>tristetraprolin</kwd><kwd>inflammation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>P30231-B</award-id><principal-award-recipient><name><surname>Versteeg</surname><given-names>Gijs A</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>P30415-B</award-id><principal-award-recipient><name><surname>Versteeg</surname><given-names>Gijs A</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>W1261</award-id><principal-award-recipient><name><surname>Kovarik</surname><given-names>Pavel</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>P33000-B</award-id><principal-award-recipient><name><surname>Kovarik</surname><given-names>Pavel</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>P31848-B</award-id><principal-award-recipient><name><surname>Kovarik</surname><given-names>Pavel</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>ERC-StG-336860</award-id><principal-award-recipient><name><surname>Zuber</surname><given-names>Johannes</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>F4710</award-id><principal-award-recipient><name><surname>Clausen</surname><given-names>Tim</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>F79</award-id><principal-award-recipient><name><surname>Clausen</surname><given-names>Tim</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>AdG 694978</award-id><principal-award-recipient><name><surname>Clausen</surname><given-names>Tim</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>HUWE1 indirectly mediates the return to cellular homeostasis after pro-inflammatory responses, which it does by controling the stability of the immune suppressor tristetraprolin.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Dynamic regulation of the immune system is essential to mount a defense against pathogens upon infection, yet shut-off the response at the appropriate time during resolution. Since most cytokines and other pro-inflammatory mediators are transcriptionally induced during infection, an essential aspect of returning to homeostatic conditions is the timely removal of their mRNAs during resolution.</p><p>Tristetraprolin (TTP; also known as ZFP36 or TIS11A) is an RNA-binding protein that interacts with AU-rich elements (ARE) present in the 3’-untranslated-regions (UTR) of many mRNAs encoding pro-inflammatory mediators (<xref ref-type="bibr" rid="bib18">Galloway et al., 2016</xref>; <xref ref-type="bibr" rid="bib30">Lai et al., 1999</xref>; <xref ref-type="bibr" rid="bib52">Sedlyarov et al., 2016</xref>). Subsequently, TTP recruits the CCR4-NOT decapping and deadenylation complex to target mRNAs, resulting in their destabilization and removal from the cell (<xref ref-type="bibr" rid="bib17">Fabian et al., 2013</xref>; <xref ref-type="bibr" rid="bib31">Lai et al., 2003</xref>; <xref ref-type="bibr" rid="bib35">Lykke-Andersen and Wagner, 2005</xref>; <xref ref-type="bibr" rid="bib47">Sandler et al., 2011</xref>; <xref ref-type="bibr" rid="bib62">Tiedje et al., 2016</xref>). TTP binds to the AREs of a multitude of mRNAs encoding cytokines and other immune-related factors, yet not all of them are destabilized (<xref ref-type="bibr" rid="bib40">Moore et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Sedlyarov et al., 2016</xref>; <xref ref-type="bibr" rid="bib62">Tiedje et al., 2016</xref>; <xref ref-type="bibr" rid="bib67">Zhang et al., 2017</xref>). This has suggested that additional -hitherto unknown- regulatory mechanisms are at play controlling TTP-dependent mRNA degradation, which may differ in various cell types.</p><p>The biological importance of TTP for proper dampening of the inflammatory response is underpinned by the observation that <italic>Zfp36</italic> (the gene encoding TTP)-deficient mice develop systemic inflammation characterized by arthritis, dermatitis, conjunctivitis, and cachexia, which has been coined TTP deficiency syndrome (<xref ref-type="bibr" rid="bib60">Taylor et al., 1996</xref>). One of the main deregulated ARE-containing mRNAs driving the inflammatory phenotype in <italic>Zfp36</italic>-deficient mice is <italic>Tnf</italic> (<xref ref-type="bibr" rid="bib5">Carballo et al., 1998</xref>; <xref ref-type="bibr" rid="bib60">Taylor et al., 1996</xref>), although additionally <italic>Il1a/b</italic>, <italic>Il23</italic>, and <italic>Ccl3</italic> have been implicated as well (<xref ref-type="bibr" rid="bib26">Kang et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Molle et al., 2013</xref>; <xref ref-type="bibr" rid="bib54">Sneezum et al., 2020</xref>).</p><p>TTP itself is regulated at the transcriptional, post-transcriptional, and post-translational levels. Most cell types express low levels of <italic>Zfp36</italic> mRNA in unstimulated conditions, the transcription of which is robustly induced by proinflammatory stimuli including the Toll-like receptor 4 (TLR4) agonist lipopolysaccharide (LPS) in myeloid cells such as macrophages (<xref ref-type="bibr" rid="bib5">Carballo et al., 1998</xref>; <xref ref-type="bibr" rid="bib29">Lai et al., 1995</xref>; <xref ref-type="bibr" rid="bib48">Sauer et al., 2006</xref>; <xref ref-type="bibr" rid="bib49">Schaljo et al., 2009</xref>; <xref ref-type="bibr" rid="bib56">Suzuki et al., 2003</xref>). At the post-translational level, TTP is phosphorylated at over 30 residues by inflammation-activated stress kinases (<xref ref-type="bibr" rid="bib4">Brook et al., 2006</xref>; <xref ref-type="bibr" rid="bib7">Clark and Dean, 2016</xref>; <xref ref-type="bibr" rid="bib21">Hitti et al., 2006</xref>; <xref ref-type="bibr" rid="bib45">Ronkina et al., 2019</xref>).</p><p>The biological relevance of most TTP phospho-sites and the identity of the involved kinases remain unknown (<xref ref-type="bibr" rid="bib7">Clark and Dean, 2016</xref>; <xref ref-type="bibr" rid="bib45">Ronkina et al., 2019</xref>). Most characterized are phosphorylation events at residues S52 and S178 in murine TTP that are mediated by the inflammation-activated kinase MK2, which acts down-stream of p38 mitogen-activated protein kinase (MAPK; <xref ref-type="bibr" rid="bib4">Brook et al., 2006</xref>; <xref ref-type="bibr" rid="bib21">Hitti et al., 2006</xref>). In mice, TTP mutants lacking these phosphorylation sites are highly unstable and rapidly degraded, yet highly biologically active (<xref ref-type="bibr" rid="bib46">Ross et al., 2015</xref>).</p><p>This has given rise to a model in which TTP is predominantly unphosphorylated and rapidly degraded in unstimulated cells, whereas pro-inflammatory cell signaling not only increases <italic>Zfp36</italic> transcription, but also TTP S52/S178 phosphorylation and stabilization through interaction with 14-3-3 proteins (<xref ref-type="bibr" rid="bib27">Kratochvill et al., 2011</xref>; <xref ref-type="bibr" rid="bib52">Sedlyarov et al., 2016</xref>). However, in this S52/S178 phosphorylated state, TTP is thought to be inactive, whereas during dephosphorylation of these residues at later times in the inflammatory response, TTP actively mediates mRNA degradation (<xref ref-type="bibr" rid="bib27">Kratochvill et al., 2011</xref>; <xref ref-type="bibr" rid="bib52">Sedlyarov et al., 2016</xref>). Nevertheless, the impact of the other 30+ phosphorylated residues on TTP stability and activity has remained largely elusive.</p><p>Proteasomes are the main degradation machines of cells for homeostatic protein turn-over (<xref ref-type="bibr" rid="bib2">Bard et al., 2018</xref>). 20S core particles contain catalytic activity, yet lack receptors for ubiquitin and ATPase activity for unfolding and translocation of proteins into the catalytic chamber. Association of 19S regulatory particles containing ubiquitin receptors and AAA+ ATPase activity assembles 26S proteasomes, which are considered the main degradative entities for poly-ubiquitinated proteins (<xref ref-type="bibr" rid="bib2">Bard et al., 2018</xref>).</p><p>TTP protein is degraded through the proteasome, as previous studies showed that 20S proteasome inhibition stabilizes TTP. Moreover, a previous study suggested that TTP may be directly degraded by 20S proteasomes in a ubiquitin-independent manner. In this context, important destabilizing intrinsically disordered regions in the N and C termini of TTP were identified and have been suggested to putatively allow direct degradation by 20S proteasomes (<xref ref-type="bibr" rid="bib4">Brook et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Ngoc et al., 2014</xref>). Yet, other regulators of intracellular TTP protein abundance have remained elusive. In this study, we set out to identify and characterize novel factors that control TTP turn-over, thereby affecting pro-inflammatory output.</p><p>Through genetic loss-of-function screening, we identified several novel determinants of TTP abundance, including the giant ubiquitin E3 ligase HUWE1. Our data indicate that TTP is strongly poly-ubiquitinated on lysines in its zinc finger domain, and degraded by the proteasome in a ubiquitin-dependent manner. Moreover, we identified a novel role for the E3 ligase HUWE1 in indirectly controlling TTP turn-over through mediating its phosphorylation via multiple stress kinases, and reduced dephosphorylation.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>TTP is degraded in a ubiquitin-dependent manner</title><p>Pro-inflammatory stimuli such as LPS drive both transcription of <italic>Zfp36</italic> (the gene encoding TTP), and phosphorylation of the TTP protein. To study how TTP protein levels are regulated, we established a macrophage cell line expressing exogenous TTP from a constitutively active promoter, uncoupling <italic>Zfp36</italic> transcription from regulatory effects on TTP protein stability in the absence or presence of pro-inflammatory signals.</p><p>Consistent with previous studies, endogenous TTP protein was rapidly induced by LPS (<xref ref-type="bibr" rid="bib5">Carballo et al., 1998</xref>; <xref ref-type="bibr" rid="bib29">Lai et al., 1995</xref>; <xref ref-type="bibr" rid="bib48">Sauer et al., 2006</xref>; <xref ref-type="bibr" rid="bib49">Schaljo et al., 2009</xref>; <xref ref-type="bibr" rid="bib56">Suzuki et al., 2003</xref>), and in the absence of de novo protein synthesis, rapidly degraded (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib4">Brook et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Ngoc et al., 2014</xref>). Treatment with proteasome inhibitor MG132 almost completely prevented TTP degradation, indicating that its degradation is predominantly through the proteasome. Under these conditions, a high-MW form of TTP accumulated, suggesting that phosphorylation is important for regulation of its stability.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>TTP is degraded by the proteasome in a ubiquitin-dependent manner.</title><p>(<bold>A</bold>) RAW264.7 murine macrophages were stimulated with LPS and incubated with the translation inhibitor cycloheximide (CHX) and the proteasome inhibitor MG132 for the indicated times (<bold>h</bold>), after which TTP levels were analyzed by western blot. (<bold>B</bold>) 3xHA-TTP-expressing RAW264.7 cells were incubated with LPS or left unstimulated. Cells were then treated with E1 enzyme inhibitor (TAK-234) or the proteasome inhibitor Epoxomicin (Epx). Protein levels were assessed by western blot. (<bold>C</bold>) RAW264.7 cells stably expressing 3xHA-tagged TTP protein were treated with Epx for 5 hr, after which TTP was immunoprecipitated, and its ubiquination analyzed by western blot. (<bold>D</bold>) Schematic representation of the TTP stability reporter construct. Constitutively expressed myc-tagged mCherry-TTP fusion protein and enhanced blue fluorescent protein (eBFP2) are translated at equimolar levels through a P2A site. (<bold>E–F</bold>) RAW264.7-Dox-Cas9-mCherry-TTP cells were stimulated with LPS for the indicated times. Subsequently, cell lysates were treated with Calf Intestinal Phosphatase (CIP) for 2 hr at 37 °C, and TTP levels analyzed by western blot. Non-saturated western blot signals for mCherry-TTP and endogenous TTP protein were quantified, normalized to ACTIN levels, and plotted. (<bold>G</bold>) RAW264.7-Dox-Cas9-mCherry-TTP cells were treated with LPS for 2 hr, after which PP1/2 inhibitor okadaic acid (OA) was added to the culture medium for 2 hr. TTP electrophoretic mobility was assessed by western blot.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig1">Figure 1A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig1">Figure 1C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig1-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata4"><label>Figure 1—source data 4.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig1">Figure 1F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig1-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata5"><label>Figure 1—source data 5.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig1">Figure 1G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig1-data5-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83159-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>TTP is degraded by the proteasome in a ubiquitin-dependent manner.</title><p>(<bold>A</bold>) 3xHA-TTP-expressing RAW264.7 cells were incubated with LPS or left unstimulated. Cells were then treated with E1 enzyme inhibitor (TAK-234) or the proteasome inhibitor Epoxomicin (Epx). Ubiquitin levels were assessed by western blot. (<bold>B</bold>) RAW264.7 cells were incubated with LPS for 2 hr, subsequently treated with the indicated inhibitors for 6 hr, and endogenous TTP quantified by Western blot. Bar graphs represent mean and s.d.; n=2 biological replicates analyzed by unpaired t-test. (<bold>C</bold>) HEK-293T cells were transiently transfected with plasmids encoding 3xHA-tagged wild-type TTP, a TTP KtoR mutant, or an empty vector. Cells were incubated with the translation inhibitor cycloheximide (CHX) and Epx for 5 hr. Immunoprecipitation was carried out using HA antibody, and TTP ubiquination was analyzed by western blot. (<bold>D</bold>) RAW264.7 cells were treated with LPS for 2 hr, subsequently incubated with CHX and Epx for 5 hr, and analyzed by IP of endogenous TTP, and subsequent WB for ubiquitin. (<bold>E</bold>) HEK-293T cells were transiently transfected with plasmids encoding 3xHA-tagged wild-type TTP, or a TTP KtoR mutant, incubated with CHX for the indicated times, and quantified by WB. Single-phase decay curves represent means and s.d. from n=3 biological replicates. (<bold>F</bold>) HEK-293T cells were transiently transfected with plasmids encoding 3xHA-tagged HA-TTP KtoR mutants, and quantified by WB. Bar graphs represent means and s.d. of n=3 biological replicates, analyzed by one-way ANOVA. (<bold>G</bold>) HEK-293T cells expressing FLAG-TTP and HA-ubiquitin were incubated for 5 hr with Epx, followed by IP for FLAG-TTP, and WB analysis using K48- or K63-specific ubiquitin antibodies. In vitro produced K48- and K63-linked ubiquitin chains were included as positive controls. (<bold>H</bold>) RAW264.7-Dox-Cas9-mCherry-TTP cells were either left unstimulated or treated with LPS for 5 hr. Subsequently, cells were incubated with CHX for 10 hr. and analyzed for mCherry-TTP protein levels by flow cytometry. (<bold>I</bold>) RAW264.7-Dox-Cas9 cells were stimulated with LPS for the indicated time. Immunoprecipitation was carried out using antibodies for TTP or an IgG control. Immunoprecipitated complexes were analysed by western blot. (<bold>J</bold>) Volcano plots representing TTP-interactome in RAW264.7 cells. RAW264.7 cells stably expressing a Dox-inducible TurboID-TTP fusion protein were treated with LPS or Epx for 4 hr., followed by 15 min. of biotin labeling in the cell medium. TurboID without fusion was used as a control. Biotinylated proteins were immunoprecipitated and submitted for nLC-MS/MS. TTP interactome is highlighted and known TTP interactors are shown adjusted p-value ≤0.05 and Fold Change (Log2) ≥1; with n=3 biological replicates.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig1-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig1-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata3"><label>Figure 1—figure supplement 1—source data 3.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig1-figsupp1-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata4"><label>Figure 1—figure supplement 1—source data 4.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig1-figsupp1-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata5"><label>Figure 1—figure supplement 1—source data 5.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig1-figsupp1-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata6"><label>Figure 1—figure supplement 1—source data 6.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig1-figsupp1-data6-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata7"><label>Figure 1—figure supplement 1—source data 7.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig1-figsupp1-data7-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata8"><label>Figure 1—figure supplement 1—source data 8.</label><caption><title>TurboID-TTP proximity labelling in RAW264.7 cells.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig1-figsupp1-data8-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83159-fig1-figsupp1-v1.tif"/></fig></fig-group><p>To investigate whether pro-inflammatory stimuli are exclusively stabilizing TTP, or also provide degradation signals, a macrophage cell line stably expressing HA-tagged TTP was established (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Under non-stimulated conditions, HA-TTP was detected as medium-range MW species migrating at and above its predicted MW of 36.7 kDa, consistent with it being partially phosphorylated under non-stimulated conditions. Stimulation with LPS resulted in rapid TTP stabilization after 30 min, followed by a reduction of its protein levels at 3 hr and 7 hr post-treatment (<xref ref-type="fig" rid="fig1">Figure 1B</xref>; lanes 2–3). This suggested that pro-inflammatory stimuli may also provide the signaling required for TTP turn-over at longer stimulation times, possibly through regulating its phosphorylation.</p><p>To determine whether TTP proteasomal degradation was mediated by ubiquitination, cells were treated with the ubiquitin E1 inhibitor TAK-243, which inhibits de novo ubiquitination (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–B</xref>). This stabilized endogenous and exogenously expressed TTP under baseline and LPS-stimulated conditions (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–B</xref>), demonstrating that TTP is degraded in a ubiquitination-dependent manner. Consistent with this notion, exogenous HA-TTP and endogenous TTP was detected to be ubiquitinated in denaturing lysates from these cells (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C-D</xref>).</p><p>Moreover, a TTP mutant in which all of its five lysine residues in the TTP zinc finger domain were mutated to arginines (KtoR), accumulated at high steady-state levels, and was substantially less ubiquitinated (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). Consistent with its strongly reduced ubiquitination, the KtoR TTP mutant was stabilized (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>). Mutation of individual lysines had no significant effects on TTP accumulation (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>), suggesting that multiple lysine residues in TTP may be functionally redundant for its ubiquitination and degradation. A TTP mutant with simultaneous mutation of four residues (K97/115/133/135 R) did significantly accumulate, albeit to a lesser extent than a mutant in which all five lysines were mutated (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>). In line with lysine poly-ubiquitination playing an important role in TTP degradation, degradative K48-linked poly-ubiquitin chains were detected on TTP, whereas non-degradative K63-linked chains were not (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G</xref>). Collectively, these results indicate that TTP is covalently poly-ubiquitinated in its TTP zinc finger domain, and that all five lysines are functionally important for TTP degradation.</p><p>To enable identification of TTP abundance regulators by genetic screening, a macrophage cell line stably expressing unstable mCherry-TTP and stable BFP was established (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). The stable BFP served as an internal control, as it is translated in equimolar amounts from the same transcript through a P2A ribosomal skip site. mCherry-TTP accumulated in cells as a stable protein under non-stimulated conditions (<xref ref-type="fig" rid="fig1">Figure 1E</xref>; top panel). In contrast, LPS stimulation initially further stabilized mCherry-TTP, yet subsequently facilitated its degradation, phenocopying its endogenous TTP counterpart (<xref ref-type="fig" rid="fig1">Figure 1E</xref>; bottom panel, and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1H</xref>). Treatment of lysates from these cells with alkaline phosphatase collapsed higher migrating endogenous and exogenous TTP species (<xref ref-type="fig" rid="fig1">Figure 1F</xref>), whereas inhibition of the phosphatases PP1 and PP2 by okadaic acid (OA) increased them (<xref ref-type="fig" rid="fig1">Figure 1G</xref>), indicating that mCherry-TTP is phosphorylated in a similar fashion as endogenous TTP.</p><p>Together, these data show that LPS-stimulation initially stabilizes TTP, whereas at later time points its induced cell signaling events direct TTP degradation.</p></sec><sec id="s2-2"><title>The E3 ligase HUWE1 is a major determinant of cellular TTP protein abundance</title><p>Next, we set out to identify cellular factors regulating TTP protein abundance. To this end, a RAW264.7 mouse macrophage cell line with Dox-inducible Cas9 was established, which in addition expresses mCherry-TTP (<xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="fig" rid="fig2">Figure 2A</xref>). To enable identification of essential genes, a cell line was established which only functionally edits in the presence of doxycycline (Dox), but not in its absence (<xref ref-type="supplementary-material" rid="fig2sdata4">Figure 2—source data 4</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Genome-wide CRISPR-Cas9 knockout screen identified the E3 ligase HUWE1 as a regulator of TTP stability.</title><p>(<bold>A</bold>) Overview of FACS-based CRISPR-Cas9 knockout screening procedure using the RAW264.7-Dox-Cas9-mCherry-TTP cell line. Cells expressing high and low levels of mCherry-TTP protein were sorted, and their integrated sgRNA coding sequences determined by next generation sequencing. (<bold>B</bold>) Read counts per million in the mCherry-TTP<sup>high</sup> cells at 3 days after Cas9 induction were compared to those in unsorted cells from the same day, sgRNA enrichment calculated by MAGeCK analysis, and log2-fold change and adjusted p-value plotted. Genes enriched in the sorted populations that met the following criteria are indicated in red: a log2 fold-change of &lt;1.8 (mCherry-TTP<sup>low</sup>) or &gt;1.8 (mCherry-TTP<sup>high</sup>), adjusted p-value &lt;0.05, not enriched in the matching eBFP2<sup>low</sup> or eBFP2<sup>high</sup> sorted cells. (<bold>C</bold>) Cas9 was induced with Dox for 5 days in RAW264.7-Dox-Cas9-mCherry-TTP cells expressing either sg<italic>ROSA</italic> or sg<italic>Huwe1</italic>. Subsequently, cells were treated with LPS for 16 hr, and TTP protein levels were assessed by western blot. HUWE1, mCherry-TTP and endogenous TTP abundance was quantified and plotted. The TTP and ACTIN panels are the left four lanes from the blot presented in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>. (<bold>D</bold>) RAW264.7-Dox-Cas9 cells expressing sg<italic>ROSA</italic> or sg<italic>Huwe1</italic> were treated with Dox for 5 days to induce Cas9. Then, cells were incubated with LPS for 16 hr or left unstimulated, and endogenous TTP protein levels analyzed by intracellular staining, followed by flow cytometry. (<bold>E</bold>) sg<italic>ROSA</italic>- or sg<italic>Huwe1</italic>-targeted RAW264.7-Dox-Cas9 cells were treated with LPS for the indicated times (<bold>h</bold>), and TTP levels were analyzed by flow cytometry. Normalized mean fluorescence intensity (MFI) was plotted. Data represent the mean and s.d.; n=3 biological replicates. ****p ≤0.0001. (<bold>F</bold>) Bone marrow-derived macrophages (BMDMs) isolated from Cas9-expressing knock-in mice were stably transduced with sg<italic>ROSA</italic> or sg<italic>Huwe1</italic>. Cells were incubated with LPS for 16 hr or left unstimulated. Endogenous TTP protein levels were determined by western blot. Quantified TTP levels normalized to VINCULIN are plotted. (<bold>G</bold>) sg<italic>ROSA</italic>- or sg<italic>Huwe1</italic>-RAW264.7-Dox-Cas9 cells were treated for 2 hr with LPS, followed by CHX chase in the continued presence of LPS. Protein lysates were harvested at the indicated time points (<bold>h</bold>). Endogenous TTP levels were measured by WB, quantified, plotted, and TTP half-life calculated. Data represent means and s.d.; n=3 biological replicates.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig2">Figure 2C</xref> and to <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig2">Figure 2F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig2">Figure 2G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig2-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata4"><label>Figure 2—source data 4.</label><caption><title>Cas9 functionality and leakiness evaluation.</title><p>RAW264.7-Dox-Cas9 cells expressing an sgRNA targeting the cell-essential gene <italic>Rrm1</italic> or the <italic>ROSA</italic> safe-harbor locus. sgRNA-positive cells were monitored by flow cytometry in the presence or absence of Dox over the indicated time period. Relative cell viability of <italic>sgRrm1</italic>-transduced cells was compared to untransduced cells, normalized to <italic>sgROSA</italic> relative cell viability and plotted.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig2-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata5"><label>Figure 2—source data 5.</label><caption><title>Adopted gating strategy of FACS-based mCherry-TTP stability regulator screen.</title><p>Representative scatter plots are shown in hierarchical order. First debris, doublets, dead (APC-Cy7 positive), Cas9-negative (GFP), mCherry- and BFP-negative cells were excluded. 5% of cells with the lowest and 1% of cells with the highest mCherry and BFP signal were sorted.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig2-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata6"><label>Figure 2—source data 6.</label><caption><title>MAGeCK analysis of D3 and D6 CRISPR screen in RAW-Dox-Cas9.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig2-data6-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83159-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Genome-wide CRISPR-Cas9 knockout screen identified the E3 ligase HUWE1 as a regulator of TTP stability.</title><p>(<bold>A</bold>) Read counts per million in the mCherry-TTP<sup>high</sup> cells at 6 days after Cas9 induction were compared to those in unsorted cells from the same day, sgRNA enrichment calculated by MAGeCK analysis, and log2-fold change and adjusted p-value plotted. Genes enriched in the sorted populations that met the following criteria are indicated in red: a log2 fold-change of &lt;1.8 (mCherry-TTP<sup>low</sup>) or &gt;1.8 (mCherry-TTP<sup>high</sup>), adjusted <italic>P</italic>-value &lt;0.05, not enriched in the matching eBFP2<sup>low</sup> or eBFP2<sup>high</sup> sorted cells. (<bold>B</bold>) RAW264.7-Dox-Cas9 cells were transduced with lentiviral vectors encoding the indicated sgRNAs. Cas9 was induced for 5 days with Dox. Subsequently, cells were treated with LPS for 16 hr, and TTP protein levels were analyzed by western blot. (<bold>C</bold>) RAW264.7-Dox-Cas9 cells expressing sg<italic>ROSA</italic> or sg<italic>Huwe1</italic> were treated with Dox for 5 days to induce Cas9. Cells were incubated with LPS for the indicated time points (<bold>h</bold>). <italic>Zfp36</italic> mRNA levels were measured by RT-qPCR and normalized to <italic>Gapdh</italic>. Data represent the mean and s.d.; n=3 biological replicates. Two-way ANOVA was performed. (<bold>D</bold>) RAW264.7-Dox-Cas9 cells expressing mCherry-IκBα were either left unstimulated or treated with LPS for 2 hr, and mCherry- IκBα protein levels analyzed by flow cytometry. (<bold>E</bold>) RAW264.7-Dox-Cas9 cells stably expressing mCherry-TTP or mCherry-IκBα fusion proteins were transduced with lentiviral expression constructs encoding sg<italic>ROSA</italic> or sg<italic>Huwe1</italic>. Knock-out was induced for 3 days by the addition of Dox. Cells were stimulated with LPS for 2 hr. (mCherry-IκBα) or 16 hr. (mCherry-TTP), after which mCherry and eBFP levels were determined by flow cytometry. (<bold>F</bold>) RAW264.7-Dox-Cas9 expressing sg<italic>ROSA</italic> or sg<italic>Huwe1</italic> were treated with Dox for 5 days to induce Cas9. Cells were pre-treated with Epx for 60 min. or left unstimulated. Subsequently, cells were incubated with LPS for the indicated times and endogenous IκBα phosphorylation and degradation was analyzed by western blot. (<bold>G</bold>) RKO-Dox-Cas9 cells expressing sg<italic>AAVS1</italic> or sg<italic>HUWE1</italic> were stimulated with Dox for 6 days, after which TTP protein levels were determined by western blot. (<bold>H</bold>) sg<italic>ROSA</italic>- or sg<italic>Huwe1</italic>-RAW264.7-Dox-Cas9 cells stably expressing 3xHA-TTP were treated for 6 hr. with LPS, followed by CHX. Protein lysates were harvested at the indicated time points (<bold>h</bold>). TTP levels were measured by western blot, quantified, plotted, and TTP half-life calculated. n=2 biological replicates, *p≤0.05.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig2-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata3"><label>Figure 2—figure supplement 1—source data 3.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1H</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig2-figsupp1-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83159-fig2-figsupp1-v1.tif"/></fig></fig-group><p>A genome-wide lentiviral sgRNA library was transduced into these cells, ensuring one integration per cell. Knock-outs were induced by treatment with Dox for three and six days to identify regulators irrespective of essential gene functions and different protein half-lives. Subsequently, TTP was destabilized by LPS treatment, cells with high and low mCherry-TTP content were sorted, and their integrated sgRNA coding sequences quantified by next-generation sequencing (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, and <xref ref-type="supplementary-material" rid="fig2sdata5">Figure 2—source data 5</xref>). In parallel, sorted cells with high or low levels of the stable BFP control (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, and <xref ref-type="supplementary-material" rid="fig2sdata5">Figure 2—source data 5</xref>) were likewise processed, and used for identifying non-specific factors.</p><p>As anticipated, factors previously reported to be important for stabilizing TTP (e.g. <italic>Mapkapk2 (Mk2</italic>), <italic>Ywhag (14-3-3γ), Mapk14 (p38</italic>)) were significantly enriched in the mCherry-TTP<sup>low</sup> cell pool (<xref ref-type="supplementary-material" rid="fig2sdata6">Figure 2—source data 6</xref>, <xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>; left and top panels, respectively). Consistent with mCherry-TTP proteasomal degradation being LPS-dependent (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), key factors for TLR4-signaling (<italic>Tlr4</italic>, <italic>Ly96 (Md2</italic>)), and components of the proteasome (<italic>Psma5</italic>, <italic>Psmb7</italic>) were significantly enriched in mCherry-TTP<sup>high</sup> sorted cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>; right and bottom panels, respectively). Moreover, various additional new candidates controlling cellular TTP abundance were identified, including the giant ubiquitin E3 ligase <italic>Huwe1</italic> (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>, right and top panels, respectively). Individual targeting of these candidates increased endogenous TTP and exogenous mCherry-TTP protein levels by western blot (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>), attesting to the validity and predictive quality of our screen.</p><p>In particular, HUWE1 was identified as a strong determinant of endogenous and exogenous TTP protein abundance by western blot (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>; compare LPS-treated samples), and flow cytometry (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), without affecting <italic>Zfp36</italic> mRNA levels (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). Consistent with an increase in protein stability, inducible <italic>Huwe1</italic> knock-out significantly increased endogenous TTP protein levels at later time points post-LPS stimulation (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Given that after initial stabilization, LPS mediates TTP degradation (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), we tested whether <italic>Huwe1</italic> knock-out affected TLR4 signaling. To this end, the effect of <italic>Huwe1</italic> loss on IκBα, which is degraded in a proteasome-dependent manner upon LPS stimulation (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>), was measured. <italic>Huwe1</italic> knock-out increased TTP protein levels (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>; top panel), but did neither affect LPS-induced degradation of mCherry-IκBα by flow cytometry (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>; bottom panel), nor endogenous IκBα by western blot (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>). This shows that the <italic>Huwe1</italic> knock-out does not affect cell signaling between TLR4 and IκBα, and this does not contribute to TTP stabilization in <italic>Huwe1</italic>-deficient cells.</p><p>Next, we determined whether the HUWE1-dependent control of TTP abundance in the RAW264.7 mouse macrophage cell line was conserved across species and cell types. To this end, <italic>HUWE1</italic> was targeted in the human colon carcinoma cell line RKO, which -unlike most myeloid cells- have low detectable levels of TTP in the absence of any stimulation (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1G</xref>). Similar to the phenotype in RAW264.7 cells, <italic>HUWE1</italic> knock-out in RKO cells strongly increased TTP protein levels (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1G</xref>), indicating that HUWE1 has a similar role in human, non-myeloid cells independent of the TLR4 axis. Moreover, targeting of <italic>Huwe1</italic> in mouse bone marrow derived macrophages (BMDMs), likewise strongly increased high and low molecular weight species of endogenous TTP (<xref ref-type="fig" rid="fig2">Figure 2F</xref>), indicating that the biological importance of <italic>Huwe1</italic> for TTP abundance is relevant in primary cells.</p><p>Lastly, we measured whether <italic>Huwe1</italic> ablation affected TTP protein half-life. To this end, <italic>sgROSA</italic> and <italic>sgHuwe1</italic> RAW264.7-Dox-Cas9 cells were continuously stimulated with LPS, chased in the presence of translation inhibitor cycloheximide (CHX), analyzed by western blot, and single-step exponential decay curves plotted. Endogenous TTP was stabilized ≥5-fold in the absence of <italic>Huwe1</italic> (estimated half-life of ~20 hr), compared to sg<italic>ROSA</italic> cells in which TTP half-life was measured to be 3.7 hr (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). In similar stability assessments with exogenously expressed TTP in the absence of LPS, <italic>Huwe1</italic> knock-out increased HA-TTP protein half-life by 83% from 35 min to 55 min (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1H</xref>). Together, these data demonstrate that loss of <italic>Huwe1</italic> increases TTP protein half-life, and positioned HUWE1 as a strong, conserved regulator of TTP protein stability.</p></sec><sec id="s2-3"><title>Loss of <italic>Huwe1</italic> decreases the half-life of pro-inflammatory mRNAs controlled by TTP</title><p>TTP is essential for the degradation of transcripts with AU-rich elements in their 3’-UTR, encoding pro-inflammatory cytokines such as TNF and IL6. Phosphorylation of S52 and S178 stabilizes TTP, yet reduces its degradation of mRNAs. In contrast, the effect of phosphorylation on other sites has remained elusive. Therefore, we reasoned that increased TTP protein levels upon <italic>Huwe1</italic> ablation could (i) either result in increased intracellular TTP protein concentrations, and consequently diminished levels of transcripts encoding pro-inflammatory cytokines, or -as a consequence of increased TTP phosphorylation- (ii) decrease the bio-active pool of TTP, resulting in equal or increased mRNA levels in <italic>Huwe1</italic> knock-out cells.</p><p>To investigate whether increased TTP levels upon <italic>Huwe1</italic> loss are biologically relevant, we measured <italic>Tnf</italic> and <italic>Il6</italic> mRNA levels in <italic>Huwe1</italic>-targeted BMDMs and RAW264.7 cells. Consistent with the fact that non-stimulated cells have very low levels of TTP, <italic>Huwe1</italic> knock-out did not alter baseline <italic>Tnf</italic> (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), or <italic>Il6</italic> (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B/C</xref>) mRNA levels.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>TTP mRNA targets are dysregulated upon <italic>Huwe1</italic> depletion.</title><p>RAW264.7-Dox-Cas9 cells expressing sg<italic>ROSA</italic> or sg<italic>Huwe1</italic> were treated with Dox for 5 days to induce Cas9. Cells were incubated with LPS for the indicated time points (h). (<bold>A</bold>) Mature <italic>Tnf</italic> mRNA levels, and (<bold>B</bold>) <italic>Tnf</italic> pre-mRNA levels were measured by RT-qPCR and normalized to <italic>Gapdh</italic>. Data represent the mean and s.d.; n=3 biological replicates. ****p ≤0.0001. Two-way ANOVA was performed. (<bold>C</bold>) RAW264.7-Dox-Cas9 cells expressing sg<italic>ROSA</italic> or sg<italic>Huwe1</italic> were treated with Dox for 5 days to induce Cas9. Cells were incubated with LPS for 3 hr, after which Actinomycin D (ActD) was added for the indicated times (min), and <italic>Tnf</italic> mRNA levels were determined by RT-qPCR. Data represent the mean and s.d.; n=3 biological replicates. **p ≤ 0.01. Unpaired t-tests were performed for the 40 min and 60 min time points.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83159-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>TTP mRNA targets are dysregulated upon <italic>Huwe1</italic> depletion.</title><p>RAW264.7-Dox-Cas9 cells expressing sg<italic>ROSA</italic> or sg<italic>Huwe1</italic> were treated with Dox for 5 days to induce Cas9. Cells were incubated with LPS for the indicated time points (h). (<bold>A</bold>) <italic>Tnf</italic> or (<bold>B</bold>) <italic>Il6</italic> mRNA levels were measured by RT-qPCR and normalized to <italic>Gapdh</italic>. Data represent the mean and s.d.; n=3 biological replicates. *p ≤ 0.05; **p ≤ 0.01; ***p≤0.001; ****p ≤0.0001. Two-way ANOVA was performed. (<bold>C</bold>) sg<italic>ROSA</italic>- or sg<italic>Huwe1</italic>-expressing BMDMs were treated with LPS as indicated. <italic>Gapdh</italic>-normalized <italic>Il6</italic> mRNA levels were measured by RT-qPCR. Data represent the mean and s.d.; with n=2 biological replicates. ****p ≤0.0001. Two-way ANOVA was performed. (<bold>D</bold>) Differentiation of sg<italic>ROSA</italic>- or sg<italic>Huwe1</italic>-expressing BMDMs after 7 days of M-CSF treatment was analyzed by F4/80 staining and analysis by flow cytometry. (<bold>E</bold>) RAW264.7-Dox-Cas9 cells expressing sg<italic>ROSA</italic> or sg<italic>Huwe1</italic> single sgRNA vectors, or sg<italic>ROSA-sgTTP</italic> or sg<italic>Huwe1-sgTTP</italic> double sgRNA vectors were incubated with LPS for the indicated times. <italic>Tnf</italic> mRNA expression was determined by RT-qPCR. Data represent the mean and s.d.; n=3 biological replicates. ****p ≤0.0001. Two-way ANOVA was performed. (<bold>F</bold>) RAW264.7-Dox-Cas9 cells expressing sg<italic>ROSA</italic> or sg<italic>Huwe1</italic> were treated with LPS for the indicated times. During the last 2 hr, Brefeldin A was added to block cytokine secretion. Intracellular TNF protein levels were analyzed by flow-cytometry. Data represent the mean and s.d.; n=3 biological replicates. **p ≤ 0.01. Two-way ANOVA was performed.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83159-fig3-figsupp1-v1.tif"/></fig></fig-group><p>LPS stimulation transcriptionally induces <italic>Tnf</italic> and <italic>Il6,</italic> and in parallel influences TTP protein stability. Loss of <italic>Huwe1</italic> resulted in significantly decreased concentrations of <italic>Tnf</italic> and <italic>Il6</italic> transcripts at 3–16 hr post-stimulation (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A–C</xref>), consistent with increased TTP protein levels in <italic>Huwe1</italic> knock-out cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). In line with TTP-dependent post-transcriptional effects, <italic>Huwe1</italic>-loss only altered mature <italic>Tnf</italic> mRNA concentrations, whereas its pre-mRNA levels remained unaffected (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), indicating that <italic>Tnf</italic> transcription was likely unaffected. Neither did any differences stem from altered macrophage differentiation from bone marrow, as no differences in F4/80 surface expression were measured between sg<italic>ROSA</italic> and sg<italic>Huwe1</italic> BMDMs (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). Instead, Actinomycin D mRNA chase experiments indicated that the decreased levels of pro-inflammatory mRNAs are consistent with a 57% decrease in <italic>Tnf</italic> mRNA stability (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Moreover, targeting of <italic>Zfp36</italic> in <italic>Huwe1</italic>-deficient cells partially rescued <italic>Tnf</italic> mRNA concentrations (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>), indicating that the effects of <italic>Huwe1</italic> loss on <italic>Tnf</italic> mRNA levels are at least in part TTP-dependent. Lastly, measurements of intracellular cytokines by flow-cytometry showed that the decreased <italic>Tnf</italic> mRNA levels in <italic>Huwe1</italic> KO cells, were matched by significantly decreased intracellular TNF protein (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>).</p><p>Taken together, these data show that loss of <italic>Huwe1</italic> increases the bio-active pool of cellular TTP, resulting in enhanced turn-over of TTP target mRNAs encoding pro-inflammatory mediators.</p></sec><sec id="s2-4"><title>HUWE1 regulates TTP phosphorylation and its increase is responsible for increased TTP stability</title><p>Since HUWE1 is a ubiquitin E3 ligase and was identified as a regulator of TTP protein stability by genetic means, we reasoned that the effects from its ablation on TTP could be direct through complex formation and ubiquitination of TTP, or indirect by influencing the activity or abundance of proteins that regulate TTP. Neither co-IP, nor TurboID proximity labeling assays identified complex formation between TTP and HUWE1 in cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1I/J</xref>).</p><p>This suggested that the effects of HUWE1 on TTP may be indirect, although direct ubiquitination of TTP by HUWE1 cannot be ruled out as their interaction may have been too transient to detect in our assays. Attempts to address direct TTP ubiquitination by HUWE1, or any of the other E3 ligases identified in the genetic screen (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–B</xref>; VHL, UBE3C, and the Cullin adapters Elongin B/C) were hindered by the inability to purify sufficient amounts of recombinant TTP protein.</p><p>Since TTP stability is regulated for an important part through phosphorylation by the stress kinase p38-MK2 axis and to a lesser extent ERK (<xref ref-type="bibr" rid="bib4">Brook et al., 2006</xref>; <xref ref-type="bibr" rid="bib12">Deleault et al., 2008</xref>; <xref ref-type="bibr" rid="bib45">Ronkina et al., 2019</xref>), we set out to determine whether <italic>Huwe1</italic> ablation would alter TTP levels indirectly by affecting the cellular concentrations or activity of these kinases. Data from <italic>Huwe1</italic> knock-out cells indicated that the effect of <italic>Huwe1</italic> loss on TTP stability was predominantly at time points after the initial two hours of LPS stimulation (<xref ref-type="fig" rid="fig2">Figure 2E</xref>) during which TTP dephosphorylation of S52/S178 happens, resulting in its degradation (<xref ref-type="bibr" rid="bib27">Kratochvill et al., 2011</xref>; <xref ref-type="bibr" rid="bib52">Sedlyarov et al., 2016</xref>). Consistent with this finding, <italic>Huwe1</italic> ablation did not significantly alter the total protein levels or change the early phosphorylation/activation kinetics of stress kinases p38, MK2, ERK, and JNK between 0 and 60 min post-LPS treatment (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–D</xref>).</p><p>In contrast, ablation of <italic>Huwe1</italic> strongly increased endogenous TTP levels upon its induction by LPS at all measured later time points from 2 to 16 hr post-stimulation (<xref ref-type="fig" rid="fig2">Figures 2E</xref> and <xref ref-type="fig" rid="fig4">4A</xref>). In the same lysates, total and activated/phosphorylated levels of p38, MK2, ERK, and JNK were determined.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>HUWE1 regulates TTP phosphorylation status, and thereby TTP stability.</title><p>(<bold>A–D</bold>) RAW264.7-Dox-Cas9 cells expressing sg<italic>ROSA</italic> or sg<italic>Huwe1</italic> were treated with Dox for 5 days to induce Cas9. Cells were incubated with LPS for the indicated time points (h). Phosphorylation of (<bold>A</bold>) p38, (<bold>B</bold>) MK2, (<bold>C</bold>) ERK, and (<bold>D</bold>) JNK was determined by western blot. (<bold>E</bold>) sg<italic>ROSA-</italic> or sg<italic>Huwe1-</italic>RAW264.7-Dox-Cas9 cells were treated with LPS or left untreated. After 2 h of LPS treatment, cells were incubated with p38i, MK2i, ERKi, JNKi, or PP1/2 inhibitor Calyculin A (CalycA). TTP levels were analyzed by flow cytometry and normalized MFI plotted. Data represent the mean and s.d.; n=3 biological replicates. **p ≤ 0.01; ***p≤ 0.001; ****p ≤0.0001. Two-way ANOVA was performed. Dotted horizontal line indicates TTP abundance in the DMSO control at 6 hr post-LPS treatment. (<bold>F</bold>) sg<italic>ROSA-</italic> or sg<italic>Huwe1-</italic>RAW264.7-Dox-Cas9 cells were treated with LPS for the indicated times. During the last 4 hr of LPS stimulation, the indicated inhibitors were added, after which endogenous TTP levels were analyzed by WB.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig4">Figure 4A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig4">Figure 4B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig4-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><label>Figure 4—source data 4.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig4">Figure 4D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig4-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata5"><label>Figure 4—source data 5.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig4">Figure 4F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig4-data5-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83159-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>HUWE1 regulates TTP phosphorylation status, and thereby its TTP stability.</title><p>(<bold>A–D</bold>) RAW264.7-Dox-Cas9 cells expressing sg<italic>ROSA</italic> or sg<italic>Huwe1</italic> were treated with Dox for 5 days to induce Cas9. Cells were incubated with LPS for the indicated time points (min). Phosphorylation of (<bold>A</bold>) p38, (<bold>B</bold>) MK2, (<bold>C</bold>) ERK, and (<bold>D</bold>) JNK was determined by western blot. Total and phosphorylated kinase levels were quantified from non-saturated western blot signals and normalized to ACTIN. The ratio of the phosphorylated protein signals to their respective total protein signals was plotted. Data represent the mean and s.d.; n=3 biological replicates. Two-way ANOVA was performed. (<bold>E</bold>) RAW264.7-Dox-Cas9 cells expressing sg<italic>ROSA</italic> or sg<italic>Huwe1</italic> were treated with Dox for 5 days to induce Cas9. Cells were incubated with LPS for the indicated time points (<bold>h</bold>). Phosphorylation of p53 was assessed by western blot. As a control for the induction of p-p53, RAW264.7-Dox-Cas9 were treated with DNA damage inducer Etoposide for 6 hr.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig4-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata3"><label>Figure 4—figure supplement 1—source data 3.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig4-figsupp1-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata4"><label>Figure 4—figure supplement 1—source data 4.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig4-figsupp1-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata5"><label>Figure 4—figure supplement 1—source data 5.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig4-figsupp1-data5-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83159-fig4-figsupp1-v1.tif"/></fig></fig-group><p>The total levels of all four kinases varied slightly between the different time points post-LPS stimulation, yet these differences were independent of the targeted locus (<italic>ROSA</italic> or <italic>Huwe1</italic>). In contrast, <italic>Huwe1</italic>-targeting consistently increased the activated phosphorylated forms of all kinases at 2 hr post-stimulation (<xref ref-type="fig" rid="fig4">Figure 4A–D</xref>). While activated p38 and ERK levels in <italic>Huwe1</italic>-targeted cells were comparable to the <italic>ROSA</italic>-targeted control, or even lower, at later time points (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>), MK2 and JNK activation was increased for prolonged times, up to 6 hr post-stimulation (<xref ref-type="fig" rid="fig4">Figure 4B–D</xref>). Importantly, in the absence of LPS stimulation, <italic>Huwe1</italic> knock-out did not affect, or even decreased, baseline phosphorylated levels of all kinases (<xref ref-type="fig" rid="fig4">Figure 4A–D</xref>). Moreover, <italic>Huwe1</italic> ablation in the presence of LPS did not induce unrelated stress responses, such as p53 activation (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>), indicating that loss of <italic>Huwe1</italic> does not induce a general stress response in the cell, but is specific for pro-inflammatory cellular conditions mediated by LPS. Together, these data indicated that in the absence of <italic>Huwe1</italic>, multiple stress kinases may be activated more, and for prolonged times.</p><p>Based on the increased levels of phosphorylated TTP (<xref ref-type="fig" rid="fig2">Figure 2C</xref>) and stress kinase activation in <italic>Huwe1</italic> knock-out cells, we hypothesized that increased phosphorylation of TTP by some or all of the four deregulated kinases could be responsible for the elevated TTP protein stability. In particular, p38 and its downstream target MK2 were prime candidates, given their importance in LPS-induced TTP stabilization through phosphorylation of S52 and S178.</p><p>We reasoned that if HUWE1-dependent stability effects on TTP occured through altering TTP phosphorylation, that either preventing TTP phosphorylation by kinase inhibition, or saturating TTP phosphorylation by phosphatase inhibition would negate TTP stabilization in <italic>Huwe1</italic> KO cells. To investigate whether the increased activity of the four individual kinases in <italic>Huwe1</italic>-targeted cells was causative for the increased TTP stability, a mixed genetic/inhibitor epistasis experiment was performed. To this end, endogenous TTP levels were assessed by intra-cellular staining in <italic>ROSA-</italic> or <italic>Huwe1-</italic>targeted cells, which were additionally treated with individual inhibitors of p38, MK2, ERK, JNK, or a combination of all four inhibitors (<xref ref-type="fig" rid="fig4">Figure 4E</xref>).</p><p>Consistent with our other results, <italic>Huwe1</italic> knock-out increased TTP protein levels in 6 hr LPS-treated DMSO control cells (<xref ref-type="fig" rid="fig4">Figure 4E</xref>; sample set 3). In line with previous reports that the p38-MK2 axis is an important determinant of TTP stability, treatment of sg<italic>ROSA</italic>-targeted cells with p38 or MK2 inhibitors significantly decreased TTP levels (<xref ref-type="fig" rid="fig4">Figure 4E</xref>; sample sets 4 and 5). However, simultaneous <italic>Huwe1</italic> knock-out still elevated TTP levels in the presence of these individual inhibitors, indicating that either HUWE1 does not affect TTP through the p38-MK2 axis, or that there are compensatory mechanisms affecting TTP stability in the absence of p38-MK2 kinase activity.</p><p>Consistent with previous findings of a minor effect of ERK activity, and no effect of JNK on TTP stabilization (<xref ref-type="bibr" rid="bib12">Deleault et al., 2008</xref>), ERK or JNK inhibition did not influence TTP levels (<xref ref-type="fig" rid="fig4">Figure 4E</xref>; sample sets 6 and 7). Moreover, the levels of TTP in the presence of either ERK or JNK inhibitors were still increased upon <italic>Huwe1</italic> knock-out, indicating that the activity of neither of these individual kinases alone is required for the HUWE1-dependent effect on TTP.</p><p>We hypothesized that the deregulated increase in activity of multiple of these four stress kinases could in a partially functionally compensatory manner contribute to elevated TTP phosphorylation (<xref ref-type="fig" rid="fig4">Figure 4A–D</xref>) and stability. Indeed, inhibition of all four kinases (4i) simultaneously rendered TTP highly unstable as expected, yet in contrast to the single kinase inhibitors, this was no longer affected by <italic>Huwe1</italic> knock-out (<xref ref-type="fig" rid="fig4">Figure 4E</xref>; sample set 8, and <xref ref-type="fig" rid="fig2">Figure 2F</xref>). From these data, we concluded that the HUWE1 effect on TTP stability is dependent on the activity of multiple stress kinases. Together, these results indicate that HUWE1 is important for curtailing TTP phosphorylation, thereby indirectly influencing TTP stability. We reasoned that the increased TTP phosphorylation in <italic>Huwe1</italic> knock-out cells could stem from either increased phosphorylation by the stress kinases, and/or decreased dephosphorylation.</p><p>Since MK2/p38, ERK, and JNK are activated/phosphorylated through independent cellular pathways, yet inactivated/dephosphorylated by the same phosphatases as TTP itself (PP1/2) (<xref ref-type="bibr" rid="bib28">Kruse et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Nguyen and Shiozaki, 1999</xref>; <xref ref-type="bibr" rid="bib57">Takekawa et al., 1998</xref>; <xref ref-type="bibr" rid="bib58">Takekawa et al., 2000</xref>; <xref ref-type="bibr" rid="bib64">Warmka et al., 2001</xref>), we reasoned that it was most likely that HUWE1 may be important to regulate PP1/2 activity or its cellular concentrations. Therefore, we hypothesized that decreased PP1/2 output in <italic>Huwe1</italic> knock-out cells could prolong TTP phosphorylation by: (<bold>i</bold>) diminishing direct TTP dephosphorylation by PP1/2, and (<bold>ii</bold>) indirectly prolonging stress kinases activation as a consequence of their diminished dephosphorylation by PP1/2.</p><p>To test this hypothesis<italic>, sgROSA</italic> or <italic>sgHuwe1</italic> cells were treated with LPS for 6 hr, and from 2 hr onward, co-incubated with PP1/2 inhibitor Calyculin A (<xref ref-type="fig" rid="fig4">Figure 4E–F</xref>). As expected, preventing dephosphorylation by this inhibitor stabilized TTP, and prevented TTP degradation by 6 hr of LPS treatment (<xref ref-type="fig" rid="fig4">Figure 4E</xref>; compare sg<italic>ROSA</italic> 6 hr LPS with sg<italic>ROSA</italic> 6 hr LPS +CalycA; sample set 9, and <xref ref-type="fig" rid="fig2">Figure 2F</xref>). In contrast to sg<italic>Huwe1</italic> samples treated for 6 hr with LPS (in which TTP protein levels were increased), <italic>Huwe1</italic> knock-out no longer increased TTP protein concentrations in the presence of Calyculin A (<xref ref-type="fig" rid="fig4">Figure 4E</xref>; compare sg<italic>Huwe1</italic> 6 hr LPS with sg<italic>Huwe1</italic> 6 hr LPS +CalycA, and <xref ref-type="fig" rid="fig2">Figure 2F</xref>).</p><p>From these results, we conclude that in the absence of HUWE1, decreased cellular output of PP1/2 may prolong stress kinase activation. Increased kinase activity and decreased dephosposphorylation of TTP by PP1/2 consequently increases TTP phosphorylation, thereby stabilizing it.</p></sec><sec id="s2-5"><title>HUWE1 controls only a small fraction of proteasome targets, and regulates the abundance of TTP paralog ZFP36L1</title><p>HUWE1 has been shown to associate with proteasomes (<xref ref-type="bibr" rid="bib3">Besche et al., 2009</xref>), the biological significance of which has remained elusive. We reasoned that HUWE1 might be important for proteasome activity, and its ablation could cause a general impaired degradation of proteasome targets such as TTP. To investigate whether this was the case, we compared the proteomes of LPS-stimulated RAW264.7-Dox-Cas9 cells in which we targeted either <italic>Huwe1</italic> or proteasome core particle component <italic>Psmb7</italic> by label-free mass-spectrometry.</p><p>As expected, <italic>Psmb7</italic> targeting altered the abundance of a large number of proteins, many of which are known targets of proteasomal degradation (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref> and <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source data 2</xref>). In contrast, <italic>Huwe1</italic> ablation significantly changed the concentrations of only a select number of proteins (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). In line with expectations of an E3 ligase, HUWE1 targets showed a trend of also being increased in <italic>Psmb7</italic> knock-out cells, and <italic>vice versa</italic> (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A/B</xref>). However, there was no clear correlation between the most affected proteins in the two genotypes, indicating that HUWE1 is likely not essential for proteasome function in cells, and that the increase of TTP in <italic>Huwe1</italic> knock-out cells is unlikely to have resulted from diminished overall proteasome activity. Among the differentially regulated proteins were factors previously identified as HUWE1 targets (<xref ref-type="bibr" rid="bib6">Cassidy et al., 2020</xref>; <xref ref-type="bibr" rid="bib61">Thompson et al., 2014</xref>; <xref ref-type="bibr" rid="bib65">Xu et al., 2016</xref>), including GRB2, CHEK1, and CDC34 (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>TTP family member ZFP36L1 abundance is increased upon <italic>HUWE1</italic> knockout in human and mouse cells.</title><p>(<bold>A</bold>) RAW264.7-Dox-Cas9 expressing sg<italic>ROSA</italic>, sg<italic>Huwe1</italic> or sg<italic>Psmb7</italic> were treated with Dox for 3 days to induce Cas9. Proteome changes were assessed by quantitative mass spectrometry. Proteins classified as HUWE1 targets are highlighted in red. Shared HUWE1 and proteasome targets are labelled in the <italic>Psmb7</italic> knock-out volcano plot. (adjusted p-value ≤0.05 and Fold Change (Log<sub>2</sub>) ≥0.5; n=3 biological replicates). (<bold>B</bold>) Venn diagram showing the overlap between proteome changes of <italic>Huwe1</italic>-targeted RAW264.7, A375, and SW620 cell lines. Shared targets are listed (adjusted p-value ≤0.05 and Fold Change (Log<sub>2</sub>) ≥0.5; n=3 biological replicates). (<bold>C</bold>) Volcano plots representing proteome changes of <italic>Huwe1</italic>- and <italic>AAVS1</italic>/<italic>ROSA</italic>-targeted A375 human melanoma cells and RAW264.7-Dox-Cas9 cells (adjusted p-value ≤0.05 and Fold Change (Log<sub>2</sub>) ≥0.5; n=3 biological replicates). The shared HUWE1 target ZFP36L1 is highlighted. (<bold>D</bold>) sg<italic>ROSA</italic> or sg<italic>Huwe1</italic> knockout RAW264.7-Dox-Cas9 cells were treated with Dox for 5 days to induce Cas9, followed by LPS treatment for the indicated times (h). Endogenous ZFP36L1 protein levels were determined by western blot.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig5">Figure 5D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig5-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Quantitative proteomics to systematically assess protein changes after HUWE1 knockout, in RAW264.7-Dox-Cas9, A375, and SW620 cell lines.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig5-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83159-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Abundance of the TTP family member ZFP36L1 is increased upon <italic>HUWE1</italic> knockout in human and mouse.</title><p>(<bold>A</bold>) Proteome changes in RAW264.7-Dox-Cas9 cells expressing sg<italic>Psmb7</italic> by quantitative mass-spectrometry. Proteins classified as PSMB7 targets are highlighted in orange and displayed in the <italic>Huwe1</italic> knock-out volcano plot. (adjusted p-value ≤0.05 and Fold Change (Log<sub>2</sub>) ≥0.5; n=3 biological replicates) (<bold>B</bold>) Venn diagram showing the overlap in proteome changes of <italic>Psmb7</italic>- and <italic>Huwe1</italic>-targeted RAW264.7-Dox-Cas9 cells. Shared targets are listed. Twenty-nine proteins were identified as common targets (adjusted p-value ≤0.05 and Fold Change (Log<sub>2</sub>) ≥0.5; n=3 biological replicates). (<bold>C</bold>) Volcano plot representing proteome changes of <italic>Huwe1</italic>- and <italic>ROSA</italic>- targeted RAW264.7-Dox-Cas9 cells. Known HUWE1 targets are highlighted in orange (adjusted p-value ≤0.05 and Fold Change (Log<sub>2</sub>) ≥0.5; n=3 biological replicates). (<bold>D–E</bold>) Proteome changes of <italic>Huwe1</italic>-targeted RAW264.7, A375, and SW620 cell lines are plotted. PP1/2 protein components in (<bold>D</bold>), and MAPK proteins in (<bold>E</bold>), are highlighted as solid dots. Only significantly enriched proteins are labelled (adjusted p-value ≤0.05 and Fold Change (Log<sub>2</sub>) ≥0.5; n=3 biological replicates).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83159-fig5-figsupp1-v1.tif"/></fig></fig-group><p>Our data so far indicated that HUWE1 is important for proper regulation of TTP phosphorylation, and that in its absence the equilibrium shifted to a hyper-phosphorylated state (<xref ref-type="fig" rid="fig4">Figure 4</xref>), dependent on a decrease in phosphatase activity, and an increase in stress kinase activity, without major effects on their protein levels.</p><p>To further assess in an unbiased manner whether <italic>Huwe1</italic> deficiency would affect MAPK or PP1/2 protein levels, we extended our proteome mass-spectrometry for two additional human cell lines (A375 and SW620). Consistent with our previous findings (<xref ref-type="fig" rid="fig4">Figure 4</xref>), <italic>Huwe1</italic> ablation did not substantially or consistently affect the protein levels of detected MAPK or PP1/2 subunits in the three cell lines (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>/E). In line with the data presented above (<xref ref-type="fig" rid="fig4">Figure 4</xref>), this suggests that the hyper-phosphorylated TTP state in <italic>Huwe1</italic>-targeted cells does not result from changes in MAPK or PP1/A protein levels.</p><p>Previous studies have indicated that HUWE1 can target broader classes of cellular substrates (<xref ref-type="bibr" rid="bib19">Grabarczyk et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Hunkeler et al., 2021</xref>), but that the targeted proteins may be cell type specific to some degree. Analysis of proteome changes in the three different cell lines identified seven proteins that were consistently increased in all <italic>Huwe1</italic>-targeted cell lines (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Moreover, the protein concentration of other proteins was changed in only two of the three cell lines, whereas it was not detected in the third (<xref ref-type="fig" rid="fig5">Figure 5B</xref>).</p><p>We reasoned that any of these common deregulated proteins in <italic>Huwe1</italic> knock-out cells could contribute to the TTP hyper-phosphorylation/stabilization phenotype. However, analysis of overlap between factors that regulate TTP abundance identified in the genetic screen (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>), and proteins deregulated by <italic>Huwe1</italic>-ablation did not identify any overlap, suggesting that these <italic>Huwe1</italic>-regulated proteins are unlikely to drive the effect on TTP protein stability.</p><p>Importantly, proteome measurements by mass-spectrometry are limited to detection of only reasonably abundant proteins. Even after LPS stimulation, no TTP peptides were identified in any of the three analyzed cell lines (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), indicating that its absolute intra-cellular concentrations in these cells are too low to be detected by this method. In contrast, peptides of its paralog ZFP36L1 were readily identified in RAW264.7 and A375 cells and among the most increased proteins identified in <italic>Huwe1</italic>-targeted cells (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). In line with this observation, independent western blot analysis of ZFP36L1 in cell lysates from <italic>Huwe1</italic>-deficient RAW264.7 cells showed that ZFP36L1 protein levels were increased in <italic>Huwe1</italic> knock-out cells (<xref ref-type="fig" rid="fig5">Figure 5D</xref>).</p><p>Collectively, these findings indicate that <italic>Huwe1</italic> ablation does not alter MAPK or PP1/2 protein levels, but that rather their differential activation alters TTP phosphorylation and stability. Moreover, ZFP36L1 abundance is regulated by HUWE1, akin to its closest related family member -TTP-, indicating that they could be regulated by HUWE1 in a conserved manner.</p></sec><sec id="s2-6"><title>Residues in the TTP 234-278 region are important for its stability</title><p>Lysines are exclusively located in the TTP zinc finger domain, and our data indicate that this is the site of poly-ubiquitination (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C–G</xref>). In line with this notion, upon mutation of the five lysine residues in its zinc finger domain (KtoR), TTP accumulated as a stable, phosphorylated species (<xref ref-type="fig" rid="fig6">Figure 6A–B</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A–B</xref>). Moreover, this mutant was no longer affected by <italic>HUWE1</italic> loss, indicating that the effects of HUWE1 on TTP stability are dependent on ubiquitination in the zinc finger domain.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Residues in the TTP 234–278 region are important for its stability.</title><p>(<bold>A</bold>) Schematic representation of 3xHA-TTP mutants. Colors denote amino acid substitutions. ZF indicates the zinc finger domain, and the three tetraprolin motifs are presented as dark grey boxes. (<bold>B–E</bold>) sg<italic>AAVS1- and</italic> sg<italic>HUWE1</italic>-depleted HEK-293T-Cas9 cells were transfected with the indicated mutants, and 3xHA-TTP stability was determined by western blot. mCherry is expressed as a stable internal control through a P2A site.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig6">Figure 6B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig6-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig6">Figure 6C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig6-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig6">Figure 6D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig6-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata4"><label>Figure 6—source data 4.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig6">Figure 6E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig6-data4-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83159-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Residues in the TTP 234–278 region are important for its stability.</title><p>(<bold>A</bold>) Alignment of mouse and human TTP and ZFP36L1 orthologs. (<bold>B</bold>) TTP protein levels from <xref ref-type="fig" rid="fig6">Figure 6B</xref> were quantified from non-saturated western blot signals, normalized to the internal control mCherry, and plotted. Data represent the mean and s.d.; n=2 biological replicates. (<bold>C</bold>) HEK-293T-Cas9 cells expressing sg<italic>AAVS1</italic> or sg<italic>HUWE1</italic> were transfected with plasmids encoding HA-tagged wtTTP or its S52/178 A mutant. HA-TTP protein levels were analyzed by WB. n=6 biological replicates, analyzed by unpaired t-test. (<bold>D</bold>) TTP protein levels from <xref ref-type="fig" rid="fig6">Figure 6C</xref> were quantified from non-saturated western blot signals, normalized to the internal control mCherry, and plotted. Data represent the mean and s.d.; n=2 biological replicates. (<bold>E</bold>) HEK-293T-Cas9 cells expressing sg<italic>AAVS1</italic> or sg<italic>HUWE1</italic> were transfected with plasmids encoding the HA-tagged TTP-Δ4 mutant. HA-TTP protein levels were quantified by WB. n=2 biological replicates, analyzed by unpaired t-test. (<bold>F–G</bold>) TTP protein levels from <xref ref-type="fig" rid="fig6">Figure 6D–E</xref> were quantified from non-saturated western blot signals, normalized to the internal control mCherry, and plotted. Data represent the mean and s.d.; n=2 biological replicates.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig6-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata2"><label>Figure 6—figure supplement 1—source data 2.</label><caption><title>Blots corresponding to <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83159-fig6-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83159-fig6-figsupp1-v1.tif"/></fig></fig-group><p>We reasoned that the E3 ligase ubiquitinating TTP at that site could bind TTP in its folded zinc finger domain, or that the mRNA-engaged TTP pool could be the predominant HUWE1-dependent target. Therefore, we addressed whether a TTP mutant with a disrupted zinc finger domain (C116R, C139R; <xref ref-type="bibr" rid="bib32">Lai et al., 2018</xref>; <xref ref-type="bibr" rid="bib38">Ming et al., 2001</xref>) would be stabilized. Zinc finger domain disruption did not accumulate at higher steady-state levels than its wtTTP counter-part, and was still increased upon <italic>HUWE1</italic> loss (<xref ref-type="fig" rid="fig6">Figure 6B</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>), demonstrating that neither recognition of the folded zinc finger domain structure by an E3 ligase, nor TTP functionality are required for the HUWE1 effects.</p><p>Our data support a role of HUWE1 in determining TTP phosphorylation, and thereby its stability. Therefore, we next analyzed whether phosphorylation of the two best-characterized TTP residues in this context (S52, S178) are important for HUWE1 effects. As for the zinc finger domain mutant, a S52A/S178A TTP mutant was still stabilized by <italic>HUWE1</italic> loss (<xref ref-type="fig" rid="fig6">Figure 6B</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>/C). This indicated that while phosphorylation of these residues importantly controls TTP stability, HUWE1 effects are likely independent of these phospho-residues.</p><p>Together, these data from full-length TTP point mutants suggest that an unknown E3 ligase likely binds TTP outside of its zinc finger domain, but ubiquitinates it on lysines inside the zinc finger domain. Moreover, we concluded that HUWE1 regulation of TTP stability and phosphorylation is independent of the MK2-stabilized S52/S178 residues. This is consistent with the finding that TTP levels were still increased in <italic>Huwe1</italic> knock-out cells treated with inhibitors of the p38 and MK2 kinases phosphorylating these two sites (<xref ref-type="fig" rid="fig4">Figure 4E</xref>; subsets 4–5). Lastly, these data indicate that TTP does not require an intact zinc finger domain for stability, suggesting that TTP engagement with target mRNAs is likely not a prerequisite for HUWE1-dependent stability regulation.</p><p>Next, we set out to determine which part of TTP regulates its HUWE1-dependent phosphorylation and stability. To this end, progressive N- and C-terminal TTP deletion mutants (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) were analyzed in cells for their steady-state concentrations, phosphorylation, and sensitivity to <italic>HUWE1</italic> ablation. Since TTP is predicted to be mostly disordered outside of its zinc finger domain (<ext-link ext-link-type="uri" xlink:href="https://alphafold.ebi.ac.uk/entry/P22893">https://alphafold.ebi.ac.uk/entry/P22893</ext-link>), we reasoned that the effects of the truncations on overall protein structure would be limited.</p><p>N-terminal deletions did neither affect TTP protein levels, its phosphorylation, nor the effect of <italic>HUWE1</italic> loss (<xref ref-type="fig" rid="fig6">Figure 6C</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D–E</xref>; deletions ΔN1-4), indicating that HUWE1 does not influence TTP stability through residues N-terminal of the zinc finger domain. Likewise, the two most C-terminal deletions did also not affect TTP stability (<xref ref-type="fig" rid="fig6">Figure 6D</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>; ΔC1-2). In contrast, further truncation of the C-terminus rendered mutant ΔC3 (259–278 region) less sensitive to <italic>HUWE1</italic> loss, yet retained its heterogeneous size distribution for phosphorylated species. Further deletion of the 234–258 region in the ΔC4 mutant strongly stabilized TTP at a homogeneously phosphorylated size, and rendered it insensitive to <italic>HUWE1</italic> knock-out (<xref ref-type="fig" rid="fig6">Figure 6D</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>). Likewise, the ΔC5 and ΔC6 mutants were insensitive to <italic>HUWE1</italic> knock-out, but accumulated as unphosphorylated TTP species. Together, these data indicate that the 234–278 region (<xref ref-type="fig" rid="fig6">Figure 6D</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>) is important for HUWE1-dependent regulation of TTP stability, and its phosphorylation status.</p><p>Since the TTP-ΔC3 mutant was stabilized in a HUWE1-insensitive manner (<xref ref-type="fig" rid="fig6">Figure 6D</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>), we reasoned that this region (259-278) could be important for proteasomal targeting (e.g. an E3 ligase binding site). In contrast, the TTP-ΔC4 mutant accumulated as a lower MW homogenously phosphorylated TTP species (<xref ref-type="fig" rid="fig6">Figure 6D</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>), suggesting that the 234–258 region regulates TTP stability by affecting its phosphorylation status (e.g. a phosphatase binding site).</p><p>To test these possibilities, we analyzed mutants in which either only the 259–278 or 234–258 regions were deleted, while retaining the rest of the protein (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Consistent with the data from <xref ref-type="fig" rid="fig6">Figure 6D</xref>, a TTP mutant only lacking the 259–278 region was strongly stabilized, accumulated predominantly as a relatively homogeneous phosphorylated species, and was insensitive to <italic>HUWE1 knock-out</italic> (<xref ref-type="fig" rid="fig6">Figure 6E</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1G</xref>). Moreover, deletion of the 234–258 region resulted in TTP hyper-phosphorylation (<xref ref-type="fig" rid="fig6">Figure 6E</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1G</xref>), consistent with the idea of it being important for phosphatase binding.</p><p>Together, these data indicate that the TTP ΔC3-specific region (259-278) is consistent with a possible binding site for an E3 ligase, whereas the ΔC4-specific region (234-258) is a likely interaction site of a phosphatase (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Importantly, the ΔC5- and ΔC6-mutants were stabilized, yet not hyperphosphorylated (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). This suggests that the phosphorylated residues contributing to TTP stabilization in <italic>HUWE1</italic> knock-out cells are likely in the possible E3 ligase binding site in the TTP ΔC3-specific region (259-278) (<xref ref-type="fig" rid="fig7">Figure 7A</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Model of HUWE1-dependent TTP regulation.</title><p>(<bold>A</bold>) Model indicating the TTP regions in its C-terminus speculated to recruit PP1/2 and an unknown E3 ligase that ubiquitinates the zinc finger domain. (<bold>B</bold>) Model of TTP stability regulation through phosphorylation in wild-type cells and <italic>Huwe1</italic>-deficient cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83159-fig7-v1.tif"/></fig><p>In summary, we provide evidence for ubiquitin-dependent proteasomal degradation as a key regulatory mechanism for TTP protein abundance in cells. A genetic screen identified HUWE1 as a strong regulator of TTP proteasomal turn-over. In the absence of <italic>Huwe1</italic>, TTP is heavily phosphorylated and stabilized, which is dependent on multiple ubiquitination sites in the TTP zinc finger domain, and phosphorylation in the 259–278 region. We propose that this region in its unphosphorylated form is also a likely binding site for an E3 ligase directing TTP ubiquitination and degradation (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Moreover, the adjacent 234–258 region is consistent with an interaction site for the main TTP phosphatases (PP1/2) (<xref ref-type="fig" rid="fig7">Figure 7A</xref>).</p><p>We propose a model in which HUWE1 under physiological conditions curtails stress kinase activation, thereby limiting their stabilizing effects on TTP (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). However, in the absence of <italic>Huwe1</italic>, the collective activity increase of these stress kinases results in TTP hyper-phosphorylation in the 259–278 region, increased TTP stability, and decreased pro-inflammatory output. Since we found that TTP phosphorylation is inversely correlated with ubiquitination and degradation, we speculate that phosphorylation in this region could prevent E3 ligase binding (<xref ref-type="fig" rid="fig7">Figure 7A</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Previous studies have predicted that TTP is disordered outside of its zinc finger domain, and showed that these unstructured regions contribute to its rapid proteasomal turn-over (<xref ref-type="bibr" rid="bib41">Ngoc et al., 2014</xref>; <xref ref-type="bibr" rid="bib46">Ross et al., 2015</xref>). Protein disorder is often associated with proteasomal turn-over, as these regions often contain degrons, accessible ubiquitination sites, or provide an initiation side for threading into the proteasome and initiating unfolding and translocation into the catalytic chamber (<xref ref-type="bibr" rid="bib1">Aufderheide et al., 2015</xref>; <xref ref-type="bibr" rid="bib63">van der Lee et al., 2014</xref>). However, previous work did not identify TTP poly-ubiquitination, and showed that incubation of TTP with purified 20S proteasomes -which lack the Ub-receptor containing 19 S regulatory particle-, were sufficient to degrade TTP (<xref ref-type="bibr" rid="bib41">Ngoc et al., 2014</xref>).</p><p>Work from Ngoc et al. showed that fusion to GFP of either the N-terminal TTP part, or the TTP C-terminal part (aa 214–436), destabilized GFP in cells (<xref ref-type="bibr" rid="bib41">Ngoc et al., 2014</xref>). Thus, the GFP destabilization was seemingly indiscriminate, and possibly caused by the disordered nature of the fusion construct per se. Since the C-terminal TTP part fused to GFP included aa 214–436, we cannot rule out that part of this effect was HUWE1-dependent. However, the discrepancy with our finding that the TTP N-terminus does not contribute to HUWE1-dependent TTP regulation, may suggest that the GFP fusions by Ngoc et al. were destabilized by more general protein principles, rather than HUWE1-specific effects.</p><p>It has been reported that oxidized, unfolded proteins could be directly degraded by 20S proteasomes (<xref ref-type="bibr" rid="bib10">Davies, 2001</xref>; <xref ref-type="bibr" rid="bib23">Inai and Nishikimi, 2002</xref>). However, the prevailing notion is that association of a regulatory particle is critical to open access to the catalytic chamber (<xref ref-type="bibr" rid="bib8">Coux et al., 1996</xref>; <xref ref-type="bibr" rid="bib10">Davies, 2001</xref>; <xref ref-type="bibr" rid="bib15">Driscoll and Goldberg, 1990</xref>; <xref ref-type="bibr" rid="bib16">Eytan et al., 1989</xref>), and efficient substrate degradation in cells. Here, we demonstrate robust poly-ubiquitination of TTP in denaturing RAW264.7 lysates, indicating that these poly-ubiquitin chains are covalently attached to TTP, and do not interact through a putative ubiquitin-interaction domain. Moreover, we show that mutation of lysines in the zinc finger domain stabilized TTP, and that an inhibitor preventing de novo ubiquitination in cells, stabilized TTP. These data demonstrate that poly-ubiquitination of TTP is essential for its degradation, which is likely mediated by 26S proteasomes.</p><p>In contrast to other published work (<xref ref-type="bibr" rid="bib41">Ngoc et al., 2014</xref>), non-degrative TRAF2-driven K63-linked poly-ubiquitination of TTP has been previously reported to mediate the balance between NFκB and JNK-dependent signaling using transfected HEK-293T cells (<xref ref-type="bibr" rid="bib50">Schichl et al., 2011</xref>). Consistent with TTP being rapidly proteasomally turned-over, we readily detected K48-linked poly-ubiquitination of TTP in the same cell system, yet failed to detect substantial K63-linked poly-ubiquitination. This dissimilarity could stem from differences in expression levels, lack of co-expression of TRAF2, or insufficicient sensitivity of the K63-specific antibody in our assays. As TNF and TLR activation activate NFκB and stress kinases -including JNK- in parallel, it will be of interest to further dissect in future studies the interplay between HUWE1-dependent phospo-regulation of TTP, and its K63-ubiquitination in stimulated myeloid cells.</p><p>Most proteins with disordered regions will eventually be degraded in in vitro reactions containing high concentrations of 20S proteasomes (<xref ref-type="bibr" rid="bib33">Liu et al., 2003</xref>; <xref ref-type="bibr" rid="bib34">Lu et al., 2015</xref>). This could explain the previous finding of ubiquitin-independent TTP degradation in vitro (<xref ref-type="bibr" rid="bib41">Ngoc et al., 2014</xref>). Future comparisons of TTP degradation kinetics of ubiquitinated and non-ubiquitinated forms in the presence of 26S proteasomes will be important to further address this issue.</p><p>Several E3 ligases to putatively poly-ubiquitinate TTP were identified in our genetic screen (<xref ref-type="fig" rid="fig2">Figure 2</xref>): HUWE1, VHL, UBE3C, and the Cullin adapters Elongin B/C. <italic>Huwe1</italic> ablation most robustly stabilized TTP, based on which we hypothesized that HUWE1 may directly poly-ubiquitinate TTP. However, multiple independent techniques, including TurboID proximity labeling and co-IPs, failed to identify an interaction between TTP and HUWE1, which suggested that it may instead indirectly influence TTP stability.</p><p>At this point, we cannot rule out that HUWE1 directly poly-ubiquitinates TTP, resulting in its proteasomal degradation. Alternatively, one or more of the other identified E3 ligases could contribute to direct TTP ubiquitination. If indeed the other E3 ligases contribute to TTP ubiquitination, the fact that their knock-out phenotype is substantially less than that of <italic>Huwe1</italic> loss (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>) may suggest that multiple of them could be functionally redundant. Irrespective of potential direct TTP ubiquitination by HUWE1, multiple lines of evidence point towards a strong contribution of HUWE1-dependent differential TTP phosphorylation as an indirect means to control TTP stability and functional activity. This is consistent with our finding that TTP phosphorylation and ubiquitination appear to be inversely correlated, as the TTP KtoR mutant accumulates as a hyper-phosphorylated species (<xref ref-type="fig" rid="fig6">Figure 6B</xref>).</p><p>Published data support a model in which TTP upon translation is initially phosphorylated by the p38/MK2 kinase axis on residues S52 and S178 (mTTP numbering), resulting in its stabilization, yet repressing TTP function (<xref ref-type="bibr" rid="bib12">Deleault et al., 2008</xref>; <xref ref-type="bibr" rid="bib21">Hitti et al., 2006</xref>; <xref ref-type="bibr" rid="bib27">Kratochvill et al., 2011</xref>; <xref ref-type="bibr" rid="bib46">Ross et al., 2015</xref>). At later stages, diminishing p38/MK2 kinase activity is thought to shift the equilibrium to dephosphorylation of TTP at these residues, rendering it active, but unstable. Under these conditions, TTP is rapidly turned over by the proteasome (<xref ref-type="bibr" rid="bib12">Deleault et al., 2008</xref>; <xref ref-type="bibr" rid="bib46">Ross et al., 2015</xref>).</p><p>Consistent with these data, we also found that an S52A/S178A mutant is unstable in the absence and presence of LPS stimulation (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>). Importantly, this mutant was still stabilized in the absence of <italic>Huwe1</italic>, indicating that the stabilizing effects of phosphorylation on S52/S178 are independent of HUWE1. Moreover, it indicates that HUWE1-dependent effects on TTP stability target other sites in TTP. Thus, S52/S178 phosphorylation seems predominantly relevant for TTP stabilization at the early (2–3 hr) time points post-LPS-stimulation (<xref ref-type="bibr" rid="bib46">Ross et al., 2015</xref>), whereas HUWE1-dependent effects occur later (between 3–16 hr) post-LPS stimulation. In contrast to S52/178, TTP phosphorylation in its C-terminal 259–278 region and its associated stabilization in the absence of <italic>Huwe1</italic>, is paralleled by decreased concentrations of known TTP mRNA targets, which suggests that phosphorylation in this region may not inhibit TTP functional output.</p><p>To uncouple LPS-induced <italic>Zfp36</italic> transcription from PTMs influencing TTP protein stability, we complemented experiments using endogenous TTP with exogenously expressed counterparts. In the absence of LPS stimulation, <italic>Huwe1</italic> loss did increase exogenous TTP, albeit rather mildly (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). In contrast, upon LPS stimulation and stress kinase activation, the effect of <italic>Huwe1</italic> knock-out was much stronger, resulting in strong TTP protein accumulation, which included a substantial fraction of phosphorylated forms (<xref ref-type="fig" rid="fig2">Figure 2C and F</xref>, and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). These results suggest that there may be low baseline levels of activated stress kinases in the cell that affect TTP stability in the absence of LPS. However, in contrast to these mild phenotypes, the predominant effects of <italic>Huwe1</italic> loss on TTP protein stability and phosphorylation occur after LPS stimulation, in line with the notion that HUWE1 regulates TTP stability through influencing stress kinase-dependent TTP phosphorylation (<xref ref-type="fig" rid="fig5">Figures 5</xref> and <xref ref-type="fig" rid="fig6">6</xref>).</p><p><italic>Huwe1</italic> loss increased the activity of multiple stress kinases (<xref ref-type="fig" rid="fig4">Figure 4A–D</xref>) without affecting their total protein levels. The previous findings that (<bold>i</bold>) the phosphorylation and activation of these kinases is controlled by PP2A (<xref ref-type="bibr" rid="bib28">Kruse et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Nguyen and Shiozaki, 1999</xref>; <xref ref-type="bibr" rid="bib57">Takekawa et al., 1998</xref>), and (<bold>ii</bold>) the observation that combined inhibition of the stress kinases, or inhibition of PP1/2 activity with Calyculin A, rescued <italic>Huwe1</italic> knock-out effects on TTP (<xref ref-type="fig" rid="fig4">Figure 4E–F</xref>), suggest that HUWE1 may be important for PP1/2 activity. In line with this notion, decreased PP1/2 activity in <italic>Huwe1</italic> knock-out cells could affect TTP phosphorylation and stability by directly affecting its dephosphorylation, and in parallel maintain high stress kinase activity, which increases TTP phosphorylation even more.</p><p>This functional interaction between HUWE1 and the activity of PP1/2 and stress kinases has not been described previously, although it should be noted that HUWE1 has been reported to control the abundance and activity of other kinases and phosphatases (<xref ref-type="bibr" rid="bib6">Cassidy et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Jang et al., 2014</xref>; <xref ref-type="bibr" rid="bib55">Su et al., 2021</xref>). Our findings broaden the understanding of how HUWE1 may indirectly influence numerous cellular proteins beyond direct recognition as ubiquitination substrates.</p><p>Taken together, our data support a model in which HUWE1 is important to maintain PP1/2 cellular output, and curtail stress kinase activation. This in turn limits phosphorylation in the TTP region spanning residues 259–278, allowing for recruitment of HUWE1 itself or another -yet unidentified- E3 ligase to that same region, subsequent poly-ubiquitination on lysine residues in the zinc finger domain, and ultimately proteasomal degradation. Phosphorylation in this region could prevent E3 ligase binding. Although the HUWE1-dependent phosphorylation effect appears to be dependent on the putative E3 ligase binding site (259-278), phosphatase recruitment to the 234–258 region in TTP seemingly controls dephosphorylation of most or all phospho-sites on TTP (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Since ZFP36L1 abundance is also strongly regulated by HUWE1, this suggests that its C-terminal region is orthologous to TTP 234–278 and how it controls HUWE1-dependent degradation could be conserved across these family members.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Vectors</title><p>The lentiviral mouse genome-wide sgRNA library (six sgRNAs/gene) has been described previously (<xref ref-type="bibr" rid="bib37">Michlits et al., 2020</xref>). Lentiviral vectors driving the expression of a single sgRNA or a dual sgRNA from a U6 promoter, and either eBFP2 or iRFP from a PGK promoter have been described previously (<xref ref-type="bibr" rid="bib11">de Almeida et al., 2021</xref>). Single sgRNA CDSs were cloned in pLentiCRISPRv2 (Addgene plasmid 52961) to perform stable knock-outs in HEK293T cells. A Dox-inducible Cas9 lentiviral vector was modified from LT3GEPIR (Addgene plasmid 111177): T3G-GFP-(miR-E)-PGK-Puro-IRES-rtTA3, in which the GFP-mirE cassette was replaced by Cas9-P2A-GFP from pLentiCRISPRv2. The TTP stability reporter (pLX-SFFV-mCherry-TTP-P2A-BFP) was constructed by cloning the open-reading frame (ORF) of murine TTP into a modified pLX303 vector (Addgene plasmid 25897). Lentiviral N-terminally HA-tagged-TTP deletions or point mutant variants were obtained by cloning the indicated variants of murine TTP ORF into a modified pLX303 vector. For this purpose, cDNAs encoding mTTP mutants were purchased from Twist Bioscience. All 3xHA-TTP constructs co-expressed mCherry through a P2A site to monitor protein expression and protein stability. All plasmids and sgRNAs used in this study are listed in <xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="table" rid="table2">Table 2</xref>.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Vectors.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Plasmid</th><th align="left" valign="bottom">Purpose</th><th align="left" valign="bottom">Reference or source</th></tr></thead><tbody><tr><td align="left" valign="bottom">pRRL-TRE3G-Cas9-P2A-GFP-PGK-IRES-rtTA3</td><td align="left" valign="bottom">Dox inducible Cas9</td><td align="left" valign="bottom">Johannes Zuber, IMP</td></tr><tr><td align="left" valign="bottom">pLX303-mCherry.TTP-P2A-BFP</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP ΔC1</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP ΔC2</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP ΔC3</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP ΔC4</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP ΔC5</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP ΔC6</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP ΔN1</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP ΔN2</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP ΔN3</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP ΔN4</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP Δ259–278</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP ΔC234-258</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP Δ206–233</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP KtoR</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP S52A S178A</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP ZNF C116R C139R</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP K97R</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP K115R</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP K133R</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP K135R</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP K141R</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP K97R/K115R</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP K97R/K115R/K133R</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP K97R/K115R/K133R/K135R</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP K135R/K141R</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP K133R/K135R/K141R</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pLX303-MYC-mCherry-P2A-3xHA.TTP K115R/K133R/K135R/K141R</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">CMV-Flag-TTP</td><td align="left" valign="bottom">TTP reporter</td><td align="left" valign="bottom">Pavel Kovarik, Max Perutz Labs</td></tr><tr><td align="left" valign="bottom">DualCRISPR-hU6-sgRNA-mU6-sgRNA-EF1as-BFP</td><td align="left" valign="bottom">Dual sgRNA</td><td align="left" valign="bottom">de Almeida M, Hinterndorfer M et al, 2021</td></tr><tr><td align="left" valign="bottom">pLentiv2-U6-PGK-iRFP670-P2A-Neo</td><td align="left" valign="bottom">Single sgRNA</td><td align="left" valign="bottom">de Almeida M, Hinterndorfer M et al, 2022</td></tr><tr><td align="left" valign="bottom">pLentiv2-U6-PGK-BFP-P2A-Neo</td><td align="left" valign="bottom">Single sgRNA</td><td align="left" valign="bottom">de Almeida M, Hinterndorfer M et al, 2023</td></tr><tr><td align="left" valign="bottom">PRRL-PBS-U6-sgRNA-EF1as-Thy1-P2A-NeoR (sgETN)</td><td align="left" valign="bottom">Library sgRNA</td><td align="left" valign="bottom">Johannes Zuber, IMP</td></tr></tbody></table></table-wrap><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>sgRNA coding sequences.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Gene</th><th align="left" valign="bottom">Species</th><th align="left" valign="bottom">Sequence (5' to 3')</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>ROSA_1 (RAW264.7 &amp; BMDMs</italic>)</td><td align="left" valign="bottom">mouse</td><td align="left" valign="bottom">AGATGGGCGGGAGTCTTC</td></tr><tr><td align="left" valign="bottom"><italic>ROSA_2 (RAW264.7 &amp; BMDMs</italic>)</td><td align="left" valign="bottom">mouse</td><td align="left" valign="bottom">TTTAGATGGGCGGGAGTCTTCGTTTA</td></tr><tr><td align="left" valign="bottom"><italic>Huwe1_1 (RAW264.7 &amp; BMDMs</italic>)</td><td align="left" valign="bottom">mouse</td><td align="left" valign="bottom">GATTTGCTGCAGTTCCAAG</td></tr><tr><td align="left" valign="bottom"><italic>Huwe1_2 (RAW264.7 &amp; BMDMs</italic>)</td><td align="left" valign="bottom">mouse</td><td align="left" valign="bottom">ATAAAATTCAAAGTGTAGTG</td></tr><tr><td align="left" valign="bottom"><italic>Psmb7_1 (RAW264.7 &amp; BMDMs</italic>)</td><td align="left" valign="bottom">mouse</td><td align="left" valign="bottom">GCTGTAACAACTCTCGGG</td></tr><tr><td align="left" valign="bottom"><italic>Psmb7_2 (RAW264.7 &amp; BMDMs</italic>)</td><td align="left" valign="bottom">mouse</td><td align="left" valign="bottom">GAAAACTGGCACTACCATCG</td></tr><tr><td align="left" valign="bottom"><italic>Vcpip1 (RAW264.7 &amp; BMDMs</italic>)</td><td align="left" valign="bottom">mouse</td><td align="left" valign="bottom">GACGTGCTCTGGTTCGATG</td></tr><tr><td align="left" valign="bottom"><italic>Ppil4 (RAW264.7 &amp; BMDMs</italic>)</td><td align="left" valign="bottom">mouse</td><td align="left" valign="bottom">GTGTTTGGTGAAGTGACAGA</td></tr><tr><td align="left" valign="bottom"><italic>Tceb1 (RAW264.7 &amp; BMDMs</italic>)</td><td align="left" valign="bottom">mouse</td><td align="left" valign="bottom">GCTGAGAATGAAACCAACG</td></tr><tr><td align="left" valign="bottom"><italic>Ube3c (RAW264.7 &amp; BMDMs</italic>)</td><td align="left" valign="bottom">mouse</td><td align="left" valign="bottom">GAGAGTCAAAGTTCAAAA</td></tr><tr><td align="left" valign="bottom"><italic>Ddx23 (RAW264.7 &amp; BMDMs</italic>)</td><td align="left" valign="bottom">mouse</td><td align="left" valign="bottom">GGATGGAGCGGGAGACCAA</td></tr><tr><td align="left" valign="bottom"><italic>Cnot10 (RAW264.7 &amp; BMDMs</italic>)</td><td align="left" valign="bottom">mouse</td><td align="left" valign="bottom">GATTTCACAGGGTAGCGG</td></tr><tr><td align="left" valign="bottom"><italic>Ttp (RAW264.7 &amp; BMDMs</italic>)</td><td align="left" valign="bottom">mouse</td><td align="left" valign="bottom">GAAGCGGGCGTTGTCGCTACG</td></tr><tr><td align="left" valign="bottom"><italic>AAVS1_1 (RKO &amp; HEK-293T</italic>)</td><td align="left" valign="bottom">human</td><td align="left" valign="bottom">CTGTGCCCCGATGCACAC</td></tr><tr><td align="left" valign="bottom"><italic>AAVS1_2 (RKO &amp; HEK-293T</italic>)</td><td align="left" valign="bottom">human</td><td align="left" valign="bottom">GCTGTGCCCCGATGCACAC</td></tr><tr><td align="left" valign="bottom"><italic>HUWE1_1 (RKO &amp; HEK-293T</italic>)</td><td align="left" valign="bottom">human</td><td align="left" valign="bottom">GTGCGAGTTATATCACTGGG</td></tr><tr><td align="left" valign="bottom"><italic>HUWE1_2 (RKO &amp; HEK-293T</italic>)</td><td align="left" valign="bottom">human</td><td align="left" valign="bottom">GTGCGAGTTATATCACTGGGTGG</td></tr><tr><td align="left" valign="bottom"><italic>AAVS1_3 (A375 &amp; SW620</italic>)</td><td align="left" valign="bottom">human</td><td align="left" valign="bottom">GCTGTGCCCCGATGCACAC</td></tr><tr><td align="left" valign="bottom"><italic>AAVS1_4 (A375 &amp; SW620</italic>)</td><td align="left" valign="bottom">human</td><td align="left" valign="bottom">GCTTGGCAAACTCACTCTT</td></tr><tr><td align="left" valign="bottom"><italic>HUWE1_3 (A375 &amp; SW620</italic>)</td><td align="left" valign="bottom">human</td><td align="left" valign="bottom">GTGCGAGTTATATCACTGGG</td></tr><tr><td align="left" valign="bottom"><italic>HUWE1_4 (A375 &amp; SW620</italic>)</td><td align="left" valign="bottom">human</td><td align="left" valign="bottom">GACAGTGGAGAATATGTCA</td></tr></tbody></table></table-wrap></sec><sec id="s4-2"><title>Cell culture and reagents</title><p>All experiments in this study have been reproduced at least twice in independent experiments. Cell lines were tested negative for mycoplasma contamination. All cell lines used in this study and their applications are listed in <xref ref-type="table" rid="table3">Table 3</xref>. None of the used cell lines are on the current list of commonly misidentified cell lines (v12). Parental cell lines were obtained from ATCC: A375 (CRL-1619), RKO (CRL-2577), SW620 (CCL-227), and authenticated by short tandem repeat analysis. These cell lines were used to generate dox-inducible Cas9 derivatives as indicated in <xref ref-type="table" rid="table3">Table 3</xref>. RAW264.7 Dox-Cas9 cells were generated by transducing RAW264.7 cells with pRRL-TRE3G-Cas9-P2A-GFP-PGK-IRES-rtTA3 lentiviral vector. Cas9 expression was induced with 500 ng/ml of Docycycline hyclate (Dox, Sigma-Aldrich, D9891) and single cells were sorted by FACS into 96-well plates using a FACSAria III cell sorter (BD Biosciences) to obtain single-cell-derived clones. Cas9 function and leakiness of the TRE3G promoter in the absence of Dox was tested in competitive proliferation assays. For mCherry-TTP reporter cells, pLX303-SFFV-mCherry-TTP-P2A-BFP was transduced into RAW264.7-Dox-Cas9 cells, and cells co-expressing mCherry and BFP were sorted by FACSAria III cell sorter into 96-well plates to obtain single-cell-derived clones. To obtain 3xHA-TTP expressing cells, pLX303-SFFV-mCherry-P2A-3xHA-TTP was transduced into RAW264.7-Dox-Cas9 cells, and cells expressing mCherry were bulk sorted using a FACSAria III. Bone marrow-derived macrophages (BMDMs) were differentiated from bone marrow isolated from femurs and tibias of 8-to-12-week-old mice from Cas9 knock-in mice of both sexes (<xref ref-type="bibr" rid="bib43">Platt et al., 2014</xref>). Femur and tibia marrow was centrifuged and cells were resuspended in DMEM. Cells were differentiated in DMEM (Sigma-Aldrich, D6429) containing recombinant M-CSF for 10 days. All cells were cultured at 37 °C and 5% CO<sub>2</sub> in a humidified incubator. All animals were maintained in the pathogen-free animal facility of the Research Institute of Molecular Pathology, and all procedures were carried out according to an ethical animal license that is approved and regularly controlled by the Austrian Veterinary Authorities (License Number: GZ: 516079/2017/14). All reagents used in this study are listed in the <xref ref-type="table" rid="table4">Table 4</xref>. All antibodies used in this study are listed in <xref ref-type="table" rid="table5">Table 5</xref>.</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Cells and culture conditions.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Cell lines and primary cells</th><th align="left" valign="bottom">Type</th><th align="left" valign="bottom">Reference or source</th><th align="left" valign="bottom">Purpose</th><th align="left" valign="bottom">Media</th><th align="left" valign="bottom">Supplements</th></tr></thead><tbody><tr><td align="left" valign="bottom">RAW264.7</td><td align="left" valign="bottom">Murine macrophages</td><td align="left" valign="bottom">ATCC TIB-71</td><td align="left" valign="bottom">parental cell line</td><td align="left" valign="bottom">Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, D6429)</td><td align="left" valign="bottom">10% FBS (Sigma-Aldrich, F7524) and 1% penicillin/streptomycin (Sigma-Aldrich, P4333)</td></tr><tr><td align="left" valign="bottom">RAW264.7-Dox-Cas9</td><td align="left" valign="bottom">Murine macrophages</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Dox-inducible Cas9</td><td align="left" valign="bottom">Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, D6429)</td><td align="left" valign="bottom">10% FBS (Sigma-Aldrich, F7524) and 1% penicillin/streptomycin (Sigma-Aldrich, P4333)</td></tr><tr><td align="left" valign="bottom">RAW264.7-Dox-Cas9 mCherry-TTP-P2A-BFP</td><td align="left" valign="bottom">Murine macrophages</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">mCherry-TTP reporter</td><td align="left" valign="bottom">Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, D6429)</td><td align="left" valign="bottom">10% FBS (Sigma-Aldrich, F7524) and 1% penicillin/streptomycin (Sigma-Aldrich, P4333)</td></tr><tr><td align="left" valign="bottom">RAW264.7-Dox-Cas9 mCherry-IkBα-P2A-BFP</td><td align="left" valign="bottom">Murine macrophages</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">mCherry-IkBα reporter</td><td align="left" valign="bottom">Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, D6429)</td><td align="left" valign="bottom">10% FBS (Sigma-Aldrich, F7524) and 1% penicillin/streptomycin (Sigma-Aldrich, P4333)</td></tr><tr><td align="left" valign="bottom">RAW264.7-Dox-Cas9 3xHA-TTP</td><td align="left" valign="bottom">Murine macrophages</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"> 3xHA-TTP reporter</td><td align="left" valign="bottom">Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, D6429)</td><td align="left" valign="bottom">10% FBS (Sigma-Aldrich, F7524) and 1% penicillin/streptomycin (Sigma-Aldrich, P4333)</td></tr><tr><td align="left" valign="bottom">Bone Marrow Derived Macrophages, BMDMs</td><td align="left" valign="bottom">Murine macrophages</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">constitutive Cas9 expression</td><td align="left" valign="bottom">Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, D6429)</td><td align="left" valign="bottom">10% FBS (Sigma-Aldrich, F7524) and 1% penicillin/streptomycin (Sigma-Aldrich, P4333)</td></tr><tr><td align="left" valign="bottom">HEK293T</td><td align="left" valign="bottom">Human kidney neural tissue</td><td align="left" valign="bottom">CRL-3216</td><td align="left" valign="bottom">3xHA-TTP mutants</td><td align="left" valign="bottom">Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, D6429)</td><td align="left" valign="bottom">10% FBS (Sigma-Aldrich, F7524) and 1% penicillin/streptomycin (Sigma-Aldrich, P4333)</td></tr><tr><td align="left" valign="bottom">Lenti-X 293T</td><td align="left" valign="bottom">Human kidney neural tissue</td><td align="left" valign="bottom">Takara, Cat# 632180</td><td align="left" valign="bottom">VLP production</td><td align="left" valign="bottom">Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, D6429)</td><td align="left" valign="bottom">10% FBS (Sigma-Aldrich, F7524) and 1% penicillin/streptomycin (Sigma-Aldrich, P4333)</td></tr><tr><td align="left" valign="bottom">RKO</td><td align="left" valign="bottom">human colon carcinoma</td><td align="left" valign="bottom">de Almeida M, Hinterndorfer M et al, 2021</td><td align="left" valign="bottom">Dox-inducible Cas9</td><td align="left" valign="bottom">RPMI 1640 (Thermo Fisher Scientific, 21875)</td><td align="left" valign="bottom"> 10% FBS (Sigma-Aldrich, F7524), L-glutamine (4  mM, Gibco), sodium pyruvate (1  mM, Sigma-Aldrich), and 1% penicillin/streptomycin (Sigma-Aldrich, P4333)</td></tr><tr><td align="left" valign="bottom">A375</td><td align="left" valign="bottom">human melanoma</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Dox-inducible Cas9</td><td align="left" valign="bottom">Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, D6429)</td><td align="left" valign="bottom">10% FBS (Sigma-Aldrich, F7524), L-glutamine (4  mM, Gibco) and 1% penicillin/streptomycin (Sigma-Aldrich, P4333)</td></tr><tr><td align="left" valign="bottom">SW620</td><td align="left" valign="bottom">human colon carcinoma</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Dox-inducible Cas9</td><td align="left" valign="bottom">Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, D6429)</td><td align="left" valign="bottom">10% FBS (Sigma-Aldrich, F7524), L-glutamine (4  mM, Gibco) and 1% penicillin/streptomycin (Sigma-Aldrich, P4333)</td></tr></tbody></table></table-wrap><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>reagents.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Description</th><th align="left" valign="bottom">Abbreviation</th><th align="left" valign="bottom">Application</th><th align="left" valign="bottom">Dilution/concentration</th><th align="left" valign="bottom">Manufacturer</th><th align="left" valign="bottom">Catalogue number</th></tr></thead><tbody><tr><td align="left" valign="bottom">Lipopolysaccharides from <italic>Escherichia coli</italic> O55:B5</td><td align="left" valign="bottom">LPS</td><td align="left" valign="bottom">Cell culture</td><td align="char" char="." valign="bottom">10 ng/ml</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">L2637</td></tr><tr><td align="left" valign="bottom">Cycloheximide</td><td align="left" valign="bottom">CHX</td><td align="left" valign="bottom">Cell culture</td><td align="left" valign="bottom">40 μg/m</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">C1988</td></tr><tr><td align="left" valign="bottom">MG132</td><td align="left" valign="bottom">MG132</td><td align="left" valign="bottom">Cell culture</td><td align="left" valign="bottom">10 μM</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">M7449</td></tr><tr><td align="left" valign="bottom">Epoxomicin</td><td align="left" valign="bottom">EPX</td><td align="left" valign="bottom">Cell culture</td><td align="left" valign="bottom">10 μM</td><td align="left" valign="bottom">Gentaur Molecular Products</td><td align="char" char="hyphen" valign="bottom">607-A2606</td></tr><tr><td align="left" valign="bottom">TAK-243</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell culture</td><td align="left" valign="bottom">0.5 μM</td><td align="left" valign="bottom">ChemScence</td><td align="left" valign="bottom">CS-0019384</td></tr><tr><td align="left" valign="bottom">Doxycycline hyclate</td><td align="left" valign="bottom">DOX</td><td align="left" valign="bottom">Cell culture</td><td align="char" char="." valign="bottom">500 ng/ml</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">D9891</td></tr><tr><td align="left" valign="bottom">G418 disulfate salt</td><td align="left" valign="bottom">G418</td><td align="left" valign="bottom">Cell culture</td><td align="char" char="endash" valign="bottom">0.5–1 mg/ml</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">A1720</td></tr><tr><td align="left" valign="bottom">PH-797804, p38 inhibitor</td><td align="left" valign="bottom">p38i</td><td align="left" valign="bottom">Cell culture</td><td align="left" valign="bottom">1 μM</td><td align="left" valign="bottom">Selleckchem</td><td align="left" valign="bottom">S2726</td></tr><tr><td align="left" valign="bottom">JNK Inhibitor II, JNK inhibitor</td><td align="left" valign="bottom">JNKi</td><td align="left" valign="bottom">Cell culture</td><td align="left" valign="bottom">20 μM</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="char" char="." valign="bottom">420119</td></tr><tr><td align="left" valign="bottom">PF-3644022, MK2 inhibitor</td><td align="left" valign="bottom">MK2i</td><td align="left" valign="bottom">Cell culture</td><td align="left" valign="bottom">10 μM</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">PZ0188</td></tr><tr><td align="left" valign="bottom">U0126, MEKi inhibitor</td><td align="left" valign="bottom">ERKi</td><td align="left" valign="bottom">Cell culture</td><td align="char" char="." valign="bottom">250 nM</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">9903</td></tr><tr><td align="left" valign="bottom">Okadaic Acid</td><td align="left" valign="bottom">OA</td><td align="left" valign="bottom">Cell culture</td><td align="left" valign="bottom">1 μM</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">5934</td></tr><tr><td align="left" valign="bottom">Calyculin A</td><td align="left" valign="bottom">CalycA</td><td align="left" valign="bottom">Cell culture</td><td align="char" char="." valign="bottom">50 nM</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">9902</td></tr><tr><td align="left" valign="bottom">Etoposide</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell culture</td><td align="left" valign="bottom">5 μM</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">E1383</td></tr><tr><td align="left" valign="bottom">Brefeldin A</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell culture</td><td align="char" char="." valign="bottom">10 ug/ml</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">B7651</td></tr></tbody></table></table-wrap><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>antibodies.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Target</th><th align="left" valign="bottom">Application</th><th align="left" valign="bottom">Dilution</th><th align="left" valign="bottom">Conjugate</th><th align="left" valign="bottom">Manufacturer</th><th align="left" valign="bottom">Catalogue number</th><th align="left" valign="bottom">Name</th><th align="left" valign="bottom">Type</th></tr></thead><tbody><tr><td align="left" valign="bottom">TTP</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">71632</td><td align="left" valign="bottom">D1I3T</td><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">Myc Tag</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:5000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">05–724</td><td align="char" char="." valign="bottom">4A6</td><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">HA tag</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">3724</td><td align="left" valign="bottom">C29F4</td><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">HECTH9</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">5695</td><td align="left" valign="bottom">AX8D1</td><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">Lasu1/Ureb1</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Bethyl</td><td align="left" valign="bottom">A300-486A</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">Vinculin</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">V9131</td><td align="left" valign="bottom">V9131</td><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">phospho-p38 MAPK, Thr180/Tyr182</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">9211</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">p38 MAPK</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">9212</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">phospho-SAPK/JNK, Thr183/Tyr185</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">9251</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">SAPK/JNK</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">9252</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">phospho-p44/42 MAPK (Erk1/2), Thr202/Tyr204</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">9101</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">p44/42 MAPK (Erk1/2)</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">4695</td><td align="char" char="." valign="bottom">137F5</td><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">p-MK2 (Thr334)</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">3007</td><td align="char" char="." valign="bottom">27B7</td><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">MK2</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">3042</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">p-p53, Ser15</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">9284</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">p-p53</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">2524</td><td align="char" char="." valign="bottom">1C12</td><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">ZFP36L1/2</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">12306–1-AP</td><td align="char" char="endash" valign="bottom">12306–1-AP</td><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">Ubiquitin</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:1000</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">sc-8017</td><td align="left" valign="bottom">P4D1</td><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">HRP-β-actin</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:20000</td><td align="left" valign="bottom">HRP</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab49900</td><td align="left" valign="bottom">AC-15</td><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">HRP anti-rabbit IgG</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:3500</td><td align="left" valign="bottom">HRP</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">7074</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Secondary</td></tr><tr><td align="left" valign="bottom">HRP anti-mouse IgG</td><td align="left" valign="bottom">Western blot</td><td align="char" char="." valign="bottom">1:3500</td><td align="left" valign="bottom">HRP</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">7076</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Secondary</td></tr><tr><td align="left" valign="bottom">TTP</td><td align="left" valign="bottom">FACS</td><td align="char" char="." valign="bottom">1:100</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">71632</td><td align="left" valign="bottom">D1I3T</td><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">HECTH9</td><td align="left" valign="bottom">FACS</td><td align="char" char="." valign="bottom">1:100</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">5695</td><td align="left" valign="bottom">AX8D1</td><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">TNF alpha</td><td align="left" valign="bottom">FACS</td><td align="char" char="." valign="bottom">1:100</td><td align="left" valign="bottom">APC</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">17-7321-82</td><td align="left" valign="bottom">MP6-XT22</td><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">Rat IgG1 kappa Isotype Control</td><td align="left" valign="bottom">FACS</td><td align="char" char="." valign="bottom">1:500</td><td align="left" valign="bottom">APC</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">17-4301-82</td><td align="left" valign="bottom">eBRG1</td><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">APC anti-CD90.1/Thy1.1</td><td align="left" valign="bottom">FACS</td><td align="char" char="." valign="bottom">1:500</td><td align="left" valign="bottom">APC</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">202526</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Secondary</td></tr><tr><td align="left" valign="bottom">Alexa Fluor Plus 594 anti-Mouse IgG</td><td align="left" valign="bottom">FACS</td><td align="char" char="." valign="bottom">1:500</td><td align="left" valign="bottom">Alexa Fluor 594</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">A-21201</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Secondary</td></tr><tr><td align="left" valign="bottom">Alexa Fluor Plus 680 anti-Rabbit IgG</td><td align="left" valign="bottom">FACS</td><td align="char" char="." valign="bottom">1:500</td><td align="left" valign="bottom">Alexa Fluor 680</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">A-21076</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Secondary</td></tr><tr><td align="left" valign="bottom">APC anti-F4/80</td><td align="left" valign="bottom">FACS</td><td align="char" char="." valign="bottom">1:100</td><td align="left" valign="bottom">APC</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">17-4801-82</td><td align="left" valign="bottom">BM8</td><td align="left" valign="bottom">Secondary</td></tr><tr><td align="left" valign="bottom">TruStain FcX mouse Fc Receptor CD16/32</td><td align="left" valign="bottom">FACS</td><td align="char" char="." valign="bottom">1:100</td><td align="left" valign="bottom"/><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">101319</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">IgG Isotype Control</td><td align="left" valign="bottom">IP</td><td align="char" char="." valign="bottom">1:300</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">2729</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">TTP</td><td align="left" valign="bottom">IP</td><td align="char" char="." valign="bottom">1:100</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">71632</td><td align="left" valign="bottom">D1I3T</td><td align="left" valign="bottom">Primary</td></tr><tr><td align="left" valign="bottom">HA tag</td><td align="left" valign="bottom">IP</td><td align="char" char="." valign="bottom">1:100</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">3724</td><td align="left" valign="bottom">C29F4</td><td align="left" valign="bottom">Primary</td></tr></tbody></table></table-wrap></sec><sec id="s4-3"><title>Transfections</title><p>All transfections were perfomed by mixing DNA and polyethylenimine (PEI, Polysciences, 23966) in a 1:3 ratio (μg DNA/μg PEI) in DMEM (Sigma-Aldrich, D6429) without supplements. Transfection was performed using 500 ng of total DNA. The day before transfection, 2×10<sup>5</sup> HEK293T cells were seeded in six-well clusters in fully supplemented media. Cells were harvested 48 hr after transfection, washed with ice cold PBS and stored at −80 °C until further processing.</p></sec><sec id="s4-4"><title>Western blot</title><p>Cells were lysed in Frackelton lysis buffer (10  mM Tris-HCl pH 7.4, 50  mM NaCl, 30  mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub>, 50  mM NaF, 2  mM EDTA, 1% Triton X-100, 1  mM DTT, 0.1  mM PMSF, and 1 X protease inhibitor cocktail). Cells were incubated for 5  min on ice and then centrifuged at 18,500 x <italic>g</italic> for 10  min at 4  °C. The supernatant was transferred to a new tube and protein concentration was determined using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, 23225). Between 20 and 40 micrograms of protein were mixed with Laemmli sample buffer supplemented with β-mercaptoethanol and boiled for 10 min. Proteins were loaded on SDS polyacrylamide gels. The percentage of the gel was chosen based on the MW of the proteins of interest. Proteins were blotted on a PVDF or on a nitrocellulose membrane at 4  °C for 16  hr at 200 mA and then for 2  hr at 400 mA in Towbin buffer (25 mM Tris-HCl pH 8.3, 192 mM glycine, and 20% ethanol) or in carbonate transfer buffer (3  mM Na<sub>2</sub>CO<sub>3</sub>, 10  mM NaHCO<sub>3</sub>, and 20% ethanol). The membrane was blocked in 5% BSA in PBS-T for 1  hr at room temperature and then incubated with the primary antibody overnight at 4  °C while shaking. The next day, the membrane was washed three times with PBS-T and incubated with HRP-coupled secondary antibody for 1  hr at room temperature and imaged with the ChemiDoc Imaging System from Bio-Rad. Relative protein levels were quantified using Image Lab (BioRad).</p></sec><sec id="s4-5"><title>Immunoprecipitation</title><p>Cells were lysed in 1  ml of RIPA lysis buffer (50  mM Tris-HCl pH 7.4, 150  mM NaCl, 1% SDS, 0.5% Sodium deoxycholate, 1% Triton X-100) supplemented with 40 mM NEM, 40 mM iodoacetamide, 25 U/ml Benzonase, 0.1  mM PMSF, and 1 X protease inhibitor. Cells were incubated on a rotating wheel at 4 °C for 30 min, and centrifuged at 20,000 x <italic>g</italic> at 4 °C for 30 min. The supernatant was transferred to a new tube and 50 µl (20% of the lysate used for the IP) were collected as input. A total of 500 µg of lysates were incubated overnight at 4  °C on a rotating wheel with an IgG Isotype control (Cell Signaling Technology, 1:300), anti-HA antibody (Cell Signaling Technology, 1:100), or anti-TTP antibody (Cell Signaling Technology, 1:100). The next day, magnetic beads (Pierce Protein A/G Magnetic Beads, Thermo Fisher Scientific, 88803) were blocked by rotation in 3% BSA in RIPA Buffer for 1 hr at 4 °C. Twenty-five µl of beads were added to 500 micrograms of lysates and rotated for 2 hr at 4 °C. Then, the beads were washed five times with 1  ml of RIPA buffer supplemented with 300 mM NaCl, and proteins were eluted in 2 X disruption buffer (2.1  M Urea, 667  mM β-mercaptoethanol and 1.4% SDS).</p></sec><sec id="s4-6"><title>Protein half-life determination</title><p>To estimate HA-TTP protein half-life, RAW264.7 Dox-Cas9 cells expressing sg<italic>Huwe1</italic> or sg<italic>ROSA</italic> were treated with Dox for 5 days before translational elongation was inhibited using 40 μg/ml of cycloheximide (CHX, Sigma-Aldrich, C1988). At indicated time points, whole cell lysates were prepared, analysed by western blot, quantified, and normalized to ACTIN levels and to time point 0 as indicated. Single exponential decay curves were determined using GraphPad Prism (v9), from which protein half-lives were calculated.</p></sec><sec id="s4-7"><title>RNA isolation, cDNA synthesis, and qPCR</title><p>Total RNA was extracted from mouse bone-marrow-derived macrophages and RAW264.7 Dox-Cas9 cells harboring non-targeting <italic>ROSA</italic> or <italic>Huwe1</italic>-targeting sgRNAs. 0.5×10<sup>6</sup> cells were lysed using Trizol reagent (Thermo-Fisher Scientific, 5596–018) and total RNA was isolated as recommended, and treated with 0.2 U/μl Turbo DNase (Thermo Fisher Scientific, AM2238). cDNA was prepared using Oligo (dT18) Primer (Thermo Fisher Scientific, S0132) or random hexamer primers (Thermo Fisher Scientific, S0142) and RevertAid Reverse Transcriptase (Thermo-Fisher Scientific, EP0441). Real-time PCR experiments were run on a Mastercycler (Biorad), using SYBR Green (Thermo-Fisher Scientific, S7567). Primers for qPCR are listed in <xref ref-type="table" rid="table6">Table 6</xref>.</p><table-wrap id="table6" position="float"><label>Table 6.</label><caption><title>qPCR primers.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Target</th><th align="left" valign="bottom">Primer</th><th align="left" valign="bottom">Sequence (5' to 3')</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="2"><italic>Il6</italic></td><td align="left" valign="bottom">FWD</td><td align="left" valign="bottom">CCAGAAACCGCTATGAAGTTCC</td></tr><tr><td align="left" valign="bottom">REV</td><td align="left" valign="bottom">TTGTCACCAGCATCAGTCCC</td></tr><tr><td align="left" valign="bottom" rowspan="2"><italic>Zfp36</italic></td><td align="left" valign="bottom">FWD</td><td align="left" valign="bottom">CTCTGCCATCTACGAGAGCC</td></tr><tr><td align="left" valign="bottom">REV</td><td align="left" valign="bottom">GATGGAGTCCGAGTTTATGTTCC</td></tr><tr><td align="left" valign="bottom" rowspan="2"><italic>Tnf</italic></td><td align="left" valign="bottom">FWD</td><td align="left" valign="bottom">GATCGGTCCCCAAAGGGATG</td></tr><tr><td align="left" valign="bottom">REV</td><td align="left" valign="bottom">CACTTGGTGGTTTGCTACGAC</td></tr><tr><td align="left" valign="bottom" rowspan="2"><italic>pre-Tnf</italic></td><td align="left" valign="bottom">FWD</td><td align="left" valign="bottom">GGCAAAGAGGAACTGTAAG</td></tr><tr><td align="left" valign="bottom">REV</td><td align="left" valign="bottom">CCATAGAACTGATGAGAGG</td></tr><tr><td align="left" valign="bottom" rowspan="2"><italic>Gapdh</italic></td><td align="left" valign="bottom">FWD</td><td align="left" valign="bottom">ATGGTGAAGGTCGGTGTGA</td></tr><tr><td align="left" valign="bottom">REV</td><td align="left" valign="bottom">TGAAGGGGTCGTTGATGG</td></tr></tbody></table></table-wrap></sec><sec id="s4-8"><title>Lentivirus production and transduction</title><p>Semiconfluent Lenti-X cells were transfected with mixes containing lentiviral transfer plasmids of interest, pCRV1-Gag-Pol (<xref ref-type="bibr" rid="bib20">Hatziioannou et al., 2004</xref>) and pHCMV-VSV-G (<xref ref-type="bibr" rid="bib66">Yee et al., 1994</xref>) using polyethylenimine (PEI, Polysciences, 23966) in a ratio of 1:3 (μg DNA/μg PEI) in DMEM without any supplements. Virus containing supernatant was clarified of cellular debris by filtration through a 0.45 μm filter. Virus-like particles were directly used after harvesting or kept at 4 °C for short-term storage. Target cells were infected in the presence of 6 μg/ml of polybrene (Sigma-Aldrich, TR1003G).</p></sec><sec id="s4-9"><title>Intracellular staining for flow cytometry</title><p>For staining of intracellular proteins, cells were collected and washed twice with PBS and subsequently fixed with 2% PFA for 15 min.at room temperature (RT). After PBS washes, cells were resuspended in ice-cold MeOH for permeabilization. At this point, fixed cells were stored in MeOH at −20 °C for a maximum of 2 days. On the day of the intracellular staining, cells were washed with PBS, and incubated for 10 min.at RT in TruStain FcX mouse Fc Receptor CD16/32 block to inhibit non-specific antibody binding. Cells were then incubated with the primary antibody or left unstained for 1 hr at RT. Following three PBS washes, cells were incubated with the secondary antibody for 15 min at 4 °C. Cells were washed two times and resuspended in FACS buffer for flow cytometric analysis on an LSRFortessa (BD Biosciences) operated by BD FACSDiva software (v8.0). FACS data were analysed in FlowJo (v10.8). Median fluorescence intensities were normalized to the control.</p></sec><sec id="s4-10"><title>FACS-based CRISPR–Cas9 screens</title><p>The genome-wide Vienna sgRNA library was was lentivirally packaged in semiconfluent Lenti-X cells (Takara) via PEI transfection. Following double harvest, the collected supernatant was cleared of cellular debris by filtration through a 0.45 μm PES filter and stored a+4 °C. The obtained virus was used to transduce RAW264.7 Dox-Cas9 cells at a multiplicity of infection (MOI) of less than 0.2 TU/cell, and 600–1000-fold library representation. The percentage of library-positive cells was determined after 4 days of transduction by immunostaining of the Thy1.1 surface marker, and subsequent flow cytometric analysis. Library-positive cells were selected with G418 (1 mg/ml, Sigma-Aldrich, A1720) and expanded. Genome editing was induced with Dox (500 ng/ml, Sigma-Aldrich, D9891) and Cas9-GFP expression was monitored by FACS. Prior to Cas9 induction with Dox (Day 0), as well as before each FACS sort, an unsorted reference sample was collected. For this, a number of cells corresponding to at least 1000-fold library representation was collected and stored at −80 °C until further processing. After 3 days and 6 days of Cas9 induction, cells were sorted at FACS. Cells were harvested, washed with PBS and stained with Fixable Viability Dye eFluor (1:1,000, eBioscience, 65-0865-14) for 30 min. Subsequently, cells were washed three times with PBS, strained through a 35 µm nylon mesh and sorted in DMEM using the FACSAria II or FACSAria III cell sorters operated by BD FACSDiva software (v8.0). For the sort the following gating strategy was used: debris, doublets, dead (Viability Dye positive), Cas9-negative (GFP), mCherry- and BFP-negative cells were excluded. 5% of cells with the lowest and 1% of cells with the highest mCherry-TTP signal were sorted into PBS; same for the BFP internal control. At least 3×10<sup>6</sup> (mCherry<sup>low</sup> and BFP<sup>low</sup>) and 5×10<sup>5</sup> (mCherry<sup>high</sup> and BFP<sup>high</sup>) cells were collected for each time point. Sorted samples were re-analysed for purity, pelleted and stored at −80 °C until further processing. The gating strategy for flow cytometric cell sorting is shown in <xref ref-type="supplementary-material" rid="fig2sdata5">Figure 2—source data 5</xref>.</p></sec><sec id="s4-11"><title>Generation of next-generation sequencing libraries</title><p>Next-generation sequencing (NGS) libraries of sorted and unsorted control samples were processed as previously described (<xref ref-type="bibr" rid="bib11">de Almeida et al., 2021</xref>). Isolated genomic DNA was subjected to two-step PCR. The first PCR allowed the amplification of the integrated sgRNA cassette, the second PCR introduced the Illumina adapters. Purified PCR products size distribution and concentration was measured using a fragment analyzer (Advanced Analytical Technologies). Equimolar ratios of the obtained libraries were pooled and sequenced on a HiSeq 2500 platform (Illumina). Primers used for library amplification are listed in <xref ref-type="table" rid="table7">Table 7</xref>. In primer sequences, NNNNNN denotes random nucleotides, XXXX denotes sample-specific barcodes.</p><table-wrap id="table7" position="float"><label>Table 7.</label><caption><title>NGS library primers.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">PCR 1</th><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/></tr></thead><tbody><tr><td align="left" valign="bottom">Primer_name</td><td align="left" valign="bottom">Direction</td><td align="left" valign="bottom">Sequence</td><td align="left" valign="bottom">Comments</td></tr><tr><td align="left" valign="bottom">sgDeepSeq_rev_XXXX</td><td align="left" valign="bottom">Rv</td><td align="left" valign="bottom">CTCTTTCCCTACACGACGCTCTTCCGATCT<break/>NNNNNNCTCATTCCAGCATAGCTCTTAAAC</td><td align="left" valign="bottom">Library preparation 1st PCR</td></tr><tr><td align="left" valign="bottom">sgDeepSeq_rev_XXXX</td><td align="left" valign="bottom">Rv</td><td align="left" valign="bottom">CTCTTTCCCTACACGACGCTCTTCCGATCT<break/>NNNNNNTCGATTCCAGCATAGCTCTTAAAC</td><td align="left" valign="bottom">Library preparation 1st PCR</td></tr><tr><td align="left" valign="bottom">sgDeepSeq_rev_XXXX</td><td align="left" valign="bottom">Rv</td><td align="left" valign="bottom">CTCTTTCCCTACACGACGCTCTTCCGATCT<break/>NNNNNNCCTATTCCAGCATAGCTCTTAAAC</td><td align="left" valign="bottom">Library preparation 1st PCR</td></tr><tr><td align="left" valign="bottom">sgDeepSeq_rev_XXXX</td><td align="left" valign="bottom">Rv</td><td align="left" valign="bottom">CTCTTTCCCTACACGACGCTCTTCCGATCT<break/>NNNNNNGAACTTCCAGCATAGCTCTTAAAC</td><td align="left" valign="bottom">Library preparation 1st PCR</td></tr><tr><td align="left" valign="bottom">sgDeepSeq_rev_XXXX</td><td align="left" valign="bottom">Rv</td><td align="left" valign="bottom">CTCTTTCCCTACACGACGCTCTTCCGATCT<break/>NNNNNNATCCTTCCAGCATAGCTCTTAAAC</td><td align="left" valign="bottom">Library preparation 1st PCR</td></tr><tr><td align="left" valign="bottom">sgDeepSeq_rev_XXXX</td><td align="left" valign="bottom">Rv</td><td align="left" valign="bottom">CTCTTTCCCTACACGACGCTCTTCCGATCT<break/>NNNNNNACTCTTCCAGCATAGCTCTTAAAC</td><td align="left" valign="bottom">Library preparation 1st PCR</td></tr><tr><td align="left" valign="bottom">sgDeepSeq_rev_XXXX</td><td align="left" valign="bottom">Rv</td><td align="left" valign="bottom">CTCTTTCCCTACACGACGCTCTTCCGATCT<break/>NNNNNNCTTCTTCCAGCATAGCTCTTAAAC</td><td align="left" valign="bottom">Library preparation 1st PCR</td></tr><tr><td align="left" valign="bottom">sgDeepSeq_rev_XXXX</td><td align="left" valign="bottom">Rv</td><td align="left" valign="bottom">CTCTTTCCCTACACGACGCTCTTCCGATCT<break/>NNNNNNCAAGTTCCAGCATAGCTCTTAAAC</td><td align="left" valign="bottom">Library preparation 1st PCR</td></tr><tr><td align="left" valign="bottom">sgDeepSeq_rev_XXXX</td><td align="left" valign="bottom">Rv</td><td align="left" valign="bottom">CTCTTTCCCTACACGACGCTCTTCCGATCT<break/>NNNNNNTGAGTTCCAGCATAGCTCTTAAAC</td><td align="left" valign="bottom">Library preparation 1st PCR</td></tr><tr><td align="left" valign="bottom">sgDeepSeq_rev_XXXX</td><td align="left" valign="bottom">Rv</td><td align="left" valign="bottom">CTCTTTCCCTACACGACGCTCTTCCGATCT<break/>NNNNNNTTCGTTCCAGCATAGCTCTTAAAC</td><td align="left" valign="bottom">Library preparation 1st PCR</td></tr><tr><td align="left" valign="bottom">sgDeepSeq_rev_XXXX</td><td align="left" valign="bottom">Rv</td><td align="left" valign="bottom">CTCTTTCCCTACACGACGCTCTTCCGATCT<break/>NNNNNNTAGGTTCCAGCATAGCTCTTAAAC</td><td align="left" valign="bottom">Library preparation 1st PCR</td></tr><tr><td align="left" valign="bottom">sgDeepSeq_rev_XXXX</td><td align="left" valign="bottom">Rv</td><td align="left" valign="bottom">CTCTTTCCCTACACGACGCTCTTCCGATCT<break/>NNNNNNTCTGTTCCAGCATAGCTCTTAAAC</td><td align="left" valign="bottom">Library preparation 1st PCR</td></tr><tr><td align="left" valign="bottom">Fwd1_hybrid_P7_Nras</td><td align="left" valign="bottom">Fwd</td><td align="left" valign="bottom">GCATACGAGATAGCTAGCCACC</td><td align="left" valign="bottom">Library preparation 1st PCR</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>PCR 2</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Primer_name</td><td align="left" valign="bottom">Direction</td><td align="left" valign="bottom">Sequence</td><td align="left" valign="bottom">Comments</td></tr><tr><td align="left" valign="bottom">Rev2_p5_sgDeepSeq</td><td align="left" valign="bottom">Rv</td><td align="left" valign="bottom">AATGATACGGCGACCACCGAGATCTACACT<break/>CTTTCCCTACACGACGCT</td><td align="left" valign="bottom">Library preparation 2nd PCR</td></tr><tr><td align="left" valign="bottom">Fwd2_p7_sgDeepSeq</td><td align="left" valign="bottom">Fwd</td><td align="left" valign="bottom">CAAGCAGAAGACGGCATACGAGATAGCTAGCCACC</td><td align="left" valign="bottom">Library preparation 2nd PCR</td></tr></tbody></table></table-wrap></sec><sec id="s4-12"><title>Analysis of pooled CRISPR screens</title><p>The analysis of the CRISPR–Cas9 screen was carried out as previously described (<xref ref-type="bibr" rid="bib11">de Almeida et al., 2021</xref>). sgRNAs enriched in day 3 and day 6 sorted samples were calculated against the unsorted population control harvested on the respective day of sorting. In addition, the dropout over time of sgRNAs was calculated by comparing the unsorted populations to the initial day 0 population.</p></sec><sec id="s4-13"><title>Quantitative proteomics</title><p>To systematically assess protein changes after <italic>Huwe1</italic> or <italic>Psmb7</italic> knockout, in RAW264.7-Dox-Cas9 cells <italic>ROSA</italic>-, <italic>Huwe1-</italic> and <italic>Psmb7</italic>-KO was induced for 2 days. Cells where incubated with LPS for the indicated times, after which 5×10<sup>5</sup> cells were washed with PBS, pelleted and snap-frozen and stored at –80 °C. Sample protein concentration was measured using standard Pierce Protein Assay Kit (Thermo Fisher Scientific, 23225), after which 40 µg of protein were processed using the iST PreOmics Sample Preparation kit 8 x (P.O. 00001) according to the manufacturer’s instructions.</p><p>Peptides were separated on an Ultimate 3000 RSLC nano-flow chromatography system (Thermo Fisher Scientific), using a pre-column for sample loading (Acclaim PepMap C18, 2 cm ×0.1 mm, 5 μm, Thermo Fisher Scientific), and a C18 analytical column (Acclaim PepMap C18, 50 cm ×0.75 mm, 2 μm, Thermo Fisher Scientific), applying a segmented linear gradient from 2% to 35% and finally 80% solvent B (80% acetonitrile, 0.1% formic acid; solvent A 0.1% formic acid) at a flow rate of 230 nL/min over 120 min. Eluting peptides were analyzed on an Exploris 480 Orbitrap mass spectrometer (Thermo Fisher Scientific), which was coupled to the column with a FAIMS pro ion-source (Thermo Fisher Scientific) using coated emitter tips (PepSep, MSWil). The mass spectrometer was operated in DIA mode with the FAIMS CV set to –45, the survey scans were obtained in a mass range of 400–900 m/z, at a resolution of 120 k at 200 m/z and a normalized AGC target at 300%. 31 MS/MS spectra with variable isolation width between 13 and 24 m/z covering 399.5–899.5 m/z range including 1 m/z windows overlap, were acquired in the HCD cell at 30% collision energy at a normalized AGC target of 1000% and a resolution of 30 k. The max. injection time was set to auto.</p><p>Raw data were processed using Spectronaut software (version 15.4.210913.50606, <ext-link ext-link-type="uri" xlink:href="https://biognosys.com/software/spectronaut/">https://biognosys.com/software/spectronaut/</ext-link>) with the DirectDIA workflow. The Uniprot mouse reference proteome (version 2021.03, <ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org">https://www.uniprot.org</ext-link>), as well as a database of most common contaminants were used. The searches were performed with full trypsin specificity and a maximum of 2 missed cleavages at a protein and peptide spectrum match false discovery rate of 1%. Carbamidomethylation of cysteine residues were set as fixed, oxidation of methionine and N-terminal acetylation as variable modifications. The global normalization and imputation were done in Spectronaut - all other parameters were left at default. Spectronaut output tables were further processed using Cassiopeia_LFQ in R (<ext-link ext-link-type="uri" xlink:href="https://github.com/moritzmadern/Cassiopeia_LFQ">https://github.com/moritzmadern/Cassiopeia_LFQ</ext-link>; <xref ref-type="bibr" rid="bib36">Madern, 2021</xref>). Contaminant proteins, protein groups identified only by one peptide and protein groups with less than two quantitative values in one experimental group, were removed for further analysis. Differences between groups were statistically evaluated using the LIMMA package (<xref ref-type="bibr" rid="bib44">Ritchie et al., 2015</xref>) in Cassiopeia_LFQ at 5% FDR (Benjamini-Hochberg).</p><p>To generate A375 AAVS1- and HUWE1-KO cells, inducible Cas9 clones of both cell lines were transduced with an sgRNA construct targeting the respective gene by lentiviral delivery. Cells were antibiotic selected for genomic integration and expanded. A375 samples were further FACS sorted for sgRNA + cells to obtain purity of &gt;99%. Cells were harvested 72 hr after Cas9 induction with Dox at final concentration of 0.2 µg/µl. A total number of 3×10<sup>6</sup> SW620 or 2.5×10<sup>6</sup> A375 cells were harvested, washed with PBS, pelleted, snap-frozen, and stored at –70 °C. Protein concentrations were measured using standard BCA assay and normalized to 50 micrograms. The protein samples were prepared with iST preOmics Sample Preparation kit 96 x (P.O. 00027) according to the manufacturer’s protocol.</p><p>The nano HPLC system (UltiMate 3000 RSLC nano system, Thermo Fisher Scientific) was coupled to an Orbitrap Eclipse Tribrid mass spectrometer equipped with a FAIMS pro interfaces and a Nanospray Flex ion source (all parts Thermo Fisher Scientific). Peptides were loaded onto a trap column (PepMap Acclaim C18, 5 mm ×300 μm ID, 5 μm particles, 100 Å pore size, Thermo Fisher Scientific) at a flow rate of 25 μl/min. using 0.1% TFA as mobile phase. After 10 minutes, the trap column was switched in line with the analytical column (PepMap Acclaim C18, 500 mm ×75 μm ID, 2 μm, 100 Å, Thermo Fisher Scientific) operated at 30 °C. Peptides were eluted using a flow rate of 230 nl/min, starting with the mobile phases 98% A (0.1% formic acid in water) and 2% B (80% acetonitrile, 0.1% formic acid) and linearly increasing to 35% B over the next 180 minutes. The Eclipse was operated in data-dependent mode, performing a full scan (m/z range 350–1500, resolution 120,000, target value 1E6) at 4 different compensation voltages (CV-45,–55, −65,–75), followed each by MS/MS scans of the most abundant ions for a cycle time of 0.75 sec per CV. MS/MS spectra were acquired using an isolation width of 1.2 m/z, target value of 3E4 and intensity threshold of 5E4, maximum injection time 20ms, HCD with a collision energy of 30, using the Iontrap for detection in the rapid scan mode. Precursor ions selected for fragmentation (include charge state 2–6) were excluded for 60 s. The monoisotopic precursor selection filter and exclude isotopes feature were enabled.</p><p>For peptide identification, the RAW-files were loaded into Proteome Discoverer (version 2.5.0.400, Thermo Fisher Scientific). All MS/MS spectra were searched using MSAmanda v2.0.0.16129 (<xref ref-type="bibr" rid="bib14">Dorfer et al., 2014</xref>). The peptide mass tolerance was set to ±10 ppm, the fragment mass tolerance to ±400 mmu, the maximal number of missed cleavages was set to 2, using tryptic enzymatic specificity without proline restriction. Peptide and protein identification were performed in two steps. For an initial search, the RAW-files were searched against the database human_uniprot_reference_2021-06-30.fasta (20,531 sequences; 11,395,157 residues), supplemented with common contaminants, using the following search parameters: alkylation of cysteine by C6H11NO was set as a fixed modification, oxidation of methionine as variable modification. The result was filtered to 1% FDR on protein level using the Percolator algorithm (<xref ref-type="bibr" rid="bib25">Käll et al., 2007</xref>) integrated in Proteome Discoverer. A sub-database of proteins identified in this search was generated for further processing. For the second search, the RAW-files were searched against the created sub-database using the same settings as above plus considering additional variable modifications: phosphorylation on serine, threonine and tyrosine, deamidation on asparagine and glutamine, and glutamine to pyro-glutamate conversion at peptide N-terminal glutamine, acetylation on protein N-terminus were set as variable modifications. The localization of the post-translational modification sites within the peptides was performed with the tool ptmRS, based on the tool phosphoRS (<xref ref-type="bibr" rid="bib59">Taus et al., 2011</xref>). Identifications were filtered again to 1% FDR on protein and PSM level, additionally an Amanda score cut-off of at least 70 was applied. Peptides were subjected to label-free quantification using IMP-apQuant (<xref ref-type="bibr" rid="bib13">Doblmann et al., 2019</xref>). Proteins were quantified by summing unique and razor peptides and applying intensity-based absolute quantification (iBAQ; <xref ref-type="bibr" rid="bib51">Schwanhäusser et al., 2011</xref>) with subsequent normalisation based on the MaxLFQ algorithm (<xref ref-type="bibr" rid="bib9">Cox et al., 2014</xref>). Proteins were filtered to be identified by a minimum of 3 quantified in at least 1 sample. Protein-abundance-normalization was done using sum normalization. Statistical significance of differentially expressed proteins was determined using limma (<xref ref-type="bibr" rid="bib53">Smyth, 2004</xref>).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Formal analysis</p></fn><fn fn-type="con" id="con10"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Supervision, Funding acquisition, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animals were maintained in the pathogen-free animal facility of the Research Institute of Molecular Pathology, and all procedures were carried out according to an ethical animal license that is approved and regularly controlled by the Austrian Veterinary Authorities (License Number: GZ: 516079/2017/14).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83159-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifiers PXD036714, PXD036715, and PXD038892. All other data generated or analyzed during this study are included in the manuscript and supporting files.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Versteeg</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>HUWE1 controls tristetraprolin proteasomal degradation by regulating its phosphorylation</data-title><source>PRIDE</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD036714">PXD036714</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Versteeg</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>HUWE1 controls tristetraprolin proteasomal degradation by regulating its phosphorylation</data-title><source>PRIDE</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD036715">PXD036715</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Versteeg</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>HUWE1 controls tristetraprolin proteasomal degradation by regulating its phosphorylation</data-title><source>PRIDE</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD038892">PXD038892</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We are grateful to Johannes Bock for establishing reagents and methodology that enabled this work. We thank Kitti Csalyi, Johanna Stranner, and Thomas Sauer at the Max Perutz Labs BioOptics FACS Facility for expert support, Markus Hartl and the Max Perutz Labs Mass Spectrometry Facility for mass spectrometry analysis, the IMP/IMBA Protein Biochemistry Core Facility for performing quantitative proteomics, and the Vienna Biocenter Core Facilities (VBCF) for Next Generation Sequencing analysis. We thank Laura Boccuni for expert advice, and the ‘Signaling Mechanisms in Cellular Homeostasis’ doctoral program community, Manuela Baccarini, Thomas Decker, Pavel Kovarik and their labs for their technical expertise and help. <italic>Funding sources:</italic> This work was funded by Stand-Alone grants (P30231-B, P30415-B), Special Research Grant (SFB grant F79), and Doctoral School grant (DK grant W1261) from the Austrian Science Fund (FWF) to GAV, FWF grants P33000-B, P31848-B, and W1261 to PK, a Starting Grant from the European Research Council (ERC-StG-336860) to JZ, the Austrian Science Fund (SFB grant F4710) to JZ, Austrian Science Fund Special Research Grant (FWF, SFB F 79) to TC, and an ERC European Union’s Horizon 2020 research and innovation programme grant (AdG 694978) to TC. SS is the recipient of a DOC fellowship of the Austrian Academy of Sciences. MS is a member of the Boehringer Ingelheim Discovery Research global post-doc program. Research at the IMP is supported by Boehringer Ingelheim and the Austrian Research Promotion Agency (Headquarter grant FFG-852936).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aufderheide</surname><given-names>A</given-names></name><name><surname>Unverdorben</surname><given-names>P</given-names></name><name><surname>Baumeister</surname><given-names>W</given-names></name><name><surname>Förster</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural disorder and its role in proteasomal degradation</article-title><source>FEBS Letters</source><volume>589</volume><fpage>2552</fpage><lpage>2560</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2015.07.034</pub-id><pub-id pub-id-type="pmid">26226424</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bard</surname><given-names>JAM</given-names></name><name><surname>Goodall</surname><given-names>EA</given-names></name><name><surname>Greene</surname><given-names>ER</given-names></name><name><surname>Jonsson</surname><given-names>E</given-names></name><name><surname>Dong</surname><given-names>KC</given-names></name><name><surname>Martin</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure and function of the 26S proteasome</article-title><source>Annual Review of Biochemistry</source><volume>87</volume><fpage>697</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-062917-011931</pub-id><pub-id pub-id-type="pmid">29652515</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besche</surname><given-names>HC</given-names></name><name><surname>Haas</surname><given-names>W</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Isolation of mammalian 26S proteasomes and p97/VCP complexes using the ubiquitin-like domain from HHR23B reveals novel proteasome-associated proteins</article-title><source>Biochemistry</source><volume>48</volume><fpage>2538</fpage><lpage>2549</lpage><pub-id pub-id-type="doi">10.1021/bi802198q</pub-id><pub-id pub-id-type="pmid">19182904</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brook</surname><given-names>M</given-names></name><name><surname>Tchen</surname><given-names>CR</given-names></name><name><surname>Santalucia</surname><given-names>T</given-names></name><name><surname>McIlrath</surname><given-names>J</given-names></name><name><surname>Arthur</surname><given-names>JSC</given-names></name><name><surname>Saklatvala</surname><given-names>J</given-names></name><name><surname>Clark</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways</article-title><source>Molecular and Cellular Biology</source><volume>26</volume><fpage>2408</fpage><lpage>2418</lpage><pub-id pub-id-type="doi">10.1128/MCB.26.6.2408-2418.2006</pub-id><pub-id pub-id-type="pmid">16508015</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carballo</surname><given-names>E</given-names></name><name><surname>Lai</surname><given-names>WS</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin</article-title><source>Science</source><volume>281</volume><fpage>1001</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1126/science.281.5379.1001</pub-id><pub-id pub-id-type="pmid">9703499</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassidy</surname><given-names>KB</given-names></name><name><surname>Bang</surname><given-names>S</given-names></name><name><surname>Kurokawa</surname><given-names>M</given-names></name><name><surname>Gerber</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Direct regulation of Chk1 protein stability by E3 ubiquitin ligase HUWE1</article-title><source>The FEBS Journal</source><volume>287</volume><fpage>1985</fpage><lpage>1999</lpage><pub-id pub-id-type="doi">10.1111/febs.15132</pub-id><pub-id pub-id-type="pmid">31713291</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>AR</given-names></name><name><surname>Dean</surname><given-names>JLE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The control of inflammation via the phosphorylation and dephosphorylation of tristetraprolin: a tale of two phosphatases</article-title><source>Biochemical Society Transactions</source><volume>44</volume><fpage>1321</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1042/BST20160166</pub-id><pub-id pub-id-type="pmid">27911715</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coux</surname><given-names>O</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Structure and functions of the 20S and 26S proteasomes</article-title><source>Annual Review of Biochemistry</source><volume>65</volume><fpage>801</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1146/annurev.bi.65.070196.004101</pub-id><pub-id pub-id-type="pmid">8811196</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Hein</surname><given-names>MY</given-names></name><name><surname>Luber</surname><given-names>CA</given-names></name><name><surname>Paron</surname><given-names>I</given-names></name><name><surname>Nagaraj</surname><given-names>N</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed maxlfq</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>13</volume><fpage>2513</fpage><lpage>2526</lpage><pub-id pub-id-type="doi">10.1074/mcp.M113.031591</pub-id><pub-id pub-id-type="pmid">24942700</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>KJA</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Degradation of oxidized proteins by the 20S proteasome</article-title><source>Biochimie</source><volume>83</volume><fpage>301</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/s0300-9084(01)01250-0</pub-id><pub-id pub-id-type="pmid">11295490</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Almeida</surname><given-names>M</given-names></name><name><surname>Hinterndorfer</surname><given-names>M</given-names></name><name><surname>Brunner</surname><given-names>H</given-names></name><name><surname>Grishkovskaya</surname><given-names>I</given-names></name><name><surname>Singh</surname><given-names>K</given-names></name><name><surname>Schleiffer</surname><given-names>A</given-names></name><name><surname>Jude</surname><given-names>J</given-names></name><name><surname>Deswal</surname><given-names>S</given-names></name><name><surname>Kalis</surname><given-names>R</given-names></name><name><surname>Vunjak</surname><given-names>M</given-names></name><name><surname>Lendl</surname><given-names>T</given-names></name><name><surname>Imre</surname><given-names>R</given-names></name><name><surname>Roitinger</surname><given-names>E</given-names></name><name><surname>Neumann</surname><given-names>T</given-names></name><name><surname>Kandolf</surname><given-names>S</given-names></name><name><surname>Schutzbier</surname><given-names>M</given-names></name><name><surname>Mechtler</surname><given-names>K</given-names></name><name><surname>Versteeg</surname><given-names>GA</given-names></name><name><surname>Haselbach</surname><given-names>D</given-names></name><name><surname>Zuber</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Akirin2 controls the nuclear import of proteasomes in vertebrates</article-title><source>Nature</source><volume>599</volume><fpage>491</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04035-8</pub-id><pub-id pub-id-type="pmid">34711951</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deleault</surname><given-names>KM</given-names></name><name><surname>Skinner</surname><given-names>SJ</given-names></name><name><surname>Brooks</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Tristetraprolin regulates TNF TNF-alpha mRNA stability via a proteasome dependent mechanism involving the combined action of the ERK and p38 pathways</article-title><source>Molecular Immunology</source><volume>45</volume><fpage>13</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2007.05.017</pub-id><pub-id pub-id-type="pmid">17606294</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doblmann</surname><given-names>J</given-names></name><name><surname>Dusberger</surname><given-names>F</given-names></name><name><surname>Imre</surname><given-names>R</given-names></name><name><surname>Hudecz</surname><given-names>O</given-names></name><name><surname>Stanek</surname><given-names>F</given-names></name><name><surname>Mechtler</surname><given-names>K</given-names></name><name><surname>Dürnberger</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>ApQuant: accurate label-free quantification by quality filtering</article-title><source>Journal of Proteome Research</source><volume>18</volume><fpage>535</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.8b00113</pub-id><pub-id pub-id-type="pmid">30351950</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorfer</surname><given-names>V</given-names></name><name><surname>Pichler</surname><given-names>P</given-names></name><name><surname>Stranzl</surname><given-names>T</given-names></name><name><surname>Stadlmann</surname><given-names>J</given-names></name><name><surname>Taus</surname><given-names>T</given-names></name><name><surname>Winkler</surname><given-names>S</given-names></name><name><surname>Mechtler</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Ms amanda, a universal identification algorithm optimized for high accuracy tandem mass spectra</article-title><source>Journal of Proteome Research</source><volume>13</volume><fpage>3679</fpage><lpage>3684</lpage><pub-id pub-id-type="doi">10.1021/pr500202e</pub-id><pub-id pub-id-type="pmid">24909410</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Driscoll</surname><given-names>J</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>The proteasome (multicatalytic protease) is a component of the 1500-kDa proteolytic complex which degrades ubiquitin-conjugated proteins</article-title><source>The Journal of Biological Chemistry</source><volume>265</volume><fpage>4789</fpage><lpage>4792</lpage><pub-id pub-id-type="pmid">2180950</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eytan</surname><given-names>E</given-names></name><name><surname>Ganoth</surname><given-names>D</given-names></name><name><surname>Armon</surname><given-names>T</given-names></name><name><surname>Hershko</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Atp-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin</article-title><source>PNAS</source><volume>86</volume><fpage>7751</fpage><lpage>7755</lpage><pub-id pub-id-type="doi">10.1073/pnas.86.20.7751</pub-id><pub-id pub-id-type="pmid">2554287</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabian</surname><given-names>MR</given-names></name><name><surname>Frank</surname><given-names>F</given-names></name><name><surname>Rouya</surname><given-names>C</given-names></name><name><surname>Siddiqui</surname><given-names>N</given-names></name><name><surname>Lai</surname><given-names>WS</given-names></name><name><surname>Karetnikov</surname><given-names>A</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name><name><surname>Nagar</surname><given-names>B</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Structural basis for the recruitment of the human Ccr4-Not deadenylase complex by tristetraprolin</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>20</volume><fpage>735</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2572</pub-id><pub-id pub-id-type="pmid">23644599</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galloway</surname><given-names>A</given-names></name><name><surname>Saveliev</surname><given-names>A</given-names></name><name><surname>Łukasiak</surname><given-names>S</given-names></name><name><surname>Hodson</surname><given-names>DJ</given-names></name><name><surname>Bolland</surname><given-names>D</given-names></name><name><surname>Balmanno</surname><given-names>K</given-names></name><name><surname>Ahlfors</surname><given-names>H</given-names></name><name><surname>Monzón-Casanova</surname><given-names>E</given-names></name><name><surname>Mannurita</surname><given-names>SC</given-names></name><name><surname>Bell</surname><given-names>LS</given-names></name><name><surname>Andrews</surname><given-names>S</given-names></name><name><surname>Díaz-Muñoz</surname><given-names>MD</given-names></name><name><surname>Cook</surname><given-names>SJ</given-names></name><name><surname>Corcoran</surname><given-names>A</given-names></name><name><surname>Turner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Rna-Binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence</article-title><source>Science</source><volume>352</volume><fpage>453</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1126/science.aad5978</pub-id><pub-id pub-id-type="pmid">27102483</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabarczyk</surname><given-names>DB</given-names></name><name><surname>Petrova</surname><given-names>OA</given-names></name><name><surname>Deszcz</surname><given-names>L</given-names></name><name><surname>Kurzbauer</surname><given-names>R</given-names></name><name><surname>Murphy</surname><given-names>P</given-names></name><name><surname>Ahel</surname><given-names>J</given-names></name><name><surname>Vogel</surname><given-names>A</given-names></name><name><surname>Gogova</surname><given-names>R</given-names></name><name><surname>Faas</surname><given-names>V</given-names></name><name><surname>Kordic</surname><given-names>D</given-names></name><name><surname>Schleiffer</surname><given-names>A</given-names></name><name><surname>Meinhart</surname><given-names>A</given-names></name><name><surname>Imre</surname><given-names>R</given-names></name><name><surname>Lehner</surname><given-names>A</given-names></name><name><surname>Neuhold</surname><given-names>J</given-names></name><name><surname>Bader</surname><given-names>G</given-names></name><name><surname>Stolt-Bergner</surname><given-names>P</given-names></name><name><surname>Böttcher</surname><given-names>J</given-names></name><name><surname>Wolkerstorfer</surname><given-names>B</given-names></name><name><surname>Fischer</surname><given-names>G</given-names></name><name><surname>Grishkovskaya</surname><given-names>I</given-names></name><name><surname>Haselbach</surname><given-names>D</given-names></name><name><surname>Kessler</surname><given-names>D</given-names></name><name><surname>Clausen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Huwe1 employs a giant substrate-binding ring to feed and regulate its HECT E3 domain</article-title><source>Nature Chemical Biology</source><volume>17</volume><fpage>1084</fpage><lpage>1092</lpage><pub-id pub-id-type="doi">10.1038/s41589-021-00831-5</pub-id><pub-id pub-id-type="pmid">34294896</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatziioannou</surname><given-names>T</given-names></name><name><surname>Cowan</surname><given-names>S</given-names></name><name><surname>Bieniasz</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Capsid-dependent and -independent postentry restriction of primate lentivirus tropism in rodent cells</article-title><source>Journal of Virology</source><volume>78</volume><fpage>1006</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1128/jvi.78.2.1006-1011.2004</pub-id><pub-id pub-id-type="pmid">14694132</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hitti</surname><given-names>E</given-names></name><name><surname>Iakovleva</surname><given-names>T</given-names></name><name><surname>Brook</surname><given-names>M</given-names></name><name><surname>Deppenmeier</surname><given-names>S</given-names></name><name><surname>Gruber</surname><given-names>AD</given-names></name><name><surname>Radzioch</surname><given-names>D</given-names></name><name><surname>Clark</surname><given-names>AR</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name><name><surname>Kotlyarov</surname><given-names>A</given-names></name><name><surname>Gaestel</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mitogen-Activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element</article-title><source>Molecular and Cellular Biology</source><volume>26</volume><fpage>2399</fpage><lpage>2407</lpage><pub-id pub-id-type="doi">10.1128/MCB.26.6.2399-2407.2006</pub-id><pub-id pub-id-type="pmid">16508014</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunkeler</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>CY</given-names></name><name><surname>Ma</surname><given-names>MW</given-names></name><name><surname>Monda</surname><given-names>JK</given-names></name><name><surname>Overwijn</surname><given-names>D</given-names></name><name><surname>Bennett</surname><given-names>EJ</given-names></name><name><surname>Fischer</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Solenoid architecture of HUWE1 contributes to ligase activity and substrate recognition</article-title><source>Molecular Cell</source><volume>81</volume><fpage>3468</fpage><lpage>3480</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2021.06.032</pub-id><pub-id pub-id-type="pmid">34314700</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inai</surname><given-names>Y</given-names></name><name><surname>Nishikimi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Increased degradation of oxidized proteins in yeast defective in 26 S proteasome assembly</article-title><source>Archives of Biochemistry and Biophysics</source><volume>404</volume><fpage>279</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/s0003-9861(02)00336-3</pub-id><pub-id pub-id-type="pmid">12147266</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>ER</given-names></name><name><surname>Shi</surname><given-names>P</given-names></name><name><surname>Bryant</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Dukhande</surname><given-names>V</given-names></name><name><surname>Gentry</surname><given-names>MS</given-names></name><name><surname>Jang</surname><given-names>H</given-names></name><name><surname>Jeoung</surname><given-names>M</given-names></name><name><surname>Galperin</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Huwe1 is a molecular link controlling Raf-1 activity supported by the Shoc2 scaffold</article-title><source>Molecular and Cellular Biology</source><volume>34</volume><fpage>3579</fpage><lpage>3593</lpage><pub-id pub-id-type="doi">10.1128/MCB.00811-14</pub-id><pub-id pub-id-type="pmid">25022756</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Käll</surname><given-names>L</given-names></name><name><surname>Canterbury</surname><given-names>JD</given-names></name><name><surname>Weston</surname><given-names>J</given-names></name><name><surname>Noble</surname><given-names>WS</given-names></name><name><surname>MacCoss</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Semi-supervised learning for peptide identification from shotgun proteomics datasets</article-title><source>Nature Methods</source><volume>4</volume><fpage>923</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1038/nmeth1113</pub-id><pub-id pub-id-type="pmid">17952086</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>JG</given-names></name><name><surname>Amar</surname><given-names>MJ</given-names></name><name><surname>Remaley</surname><given-names>AT</given-names></name><name><surname>Kwon</surname><given-names>J</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Hwang</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Zinc finger protein tristetraprolin interacts with CCL3 mrna and regulates tissue inflammation</article-title><source>Journal of Immunology</source><volume>187</volume><fpage>2696</fpage><lpage>2701</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1101149</pub-id><pub-id pub-id-type="pmid">21784977</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kratochvill</surname><given-names>F</given-names></name><name><surname>Machacek</surname><given-names>C</given-names></name><name><surname>Vogl</surname><given-names>C</given-names></name><name><surname>Ebner</surname><given-names>F</given-names></name><name><surname>Sedlyarov</surname><given-names>V</given-names></name><name><surname>Gruber</surname><given-names>AR</given-names></name><name><surname>Hartweger</surname><given-names>H</given-names></name><name><surname>Vielnascher</surname><given-names>R</given-names></name><name><surname>Karaghiosoff</surname><given-names>M</given-names></name><name><surname>Rülicke</surname><given-names>T</given-names></name><name><surname>Müller</surname><given-names>M</given-names></name><name><surname>Hofacker</surname><given-names>I</given-names></name><name><surname>Lang</surname><given-names>R</given-names></name><name><surname>Kovarik</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Tristetraprolin-driven regulatory circuit controls quality and timing of mRNA decay in inflammation</article-title><source>Molecular Systems Biology</source><volume>7</volume><elocation-id>560</elocation-id><pub-id pub-id-type="doi">10.1038/msb.2011.93</pub-id><pub-id pub-id-type="pmid">22186734</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruse</surname><given-names>T</given-names></name><name><surname>Gnosa</surname><given-names>SP</given-names></name><name><surname>Nasa</surname><given-names>I</given-names></name><name><surname>Garvanska</surname><given-names>DH</given-names></name><name><surname>Hein</surname><given-names>JB</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Samsøe-Petersen</surname><given-names>J</given-names></name><name><surname>Lopez-Mendez</surname><given-names>B</given-names></name><name><surname>Hertz</surname><given-names>EPT</given-names></name><name><surname>Schwarz</surname><given-names>J</given-names></name><name><surname>Pena</surname><given-names>HS</given-names></name><name><surname>Nikodemus</surname><given-names>D</given-names></name><name><surname>Kveiborg</surname><given-names>M</given-names></name><name><surname>Kettenbach</surname><given-names>AN</given-names></name><name><surname>Nilsson</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanisms of site-specific dephosphorylation and kinase opposition imposed by PP2A regulatory subunits</article-title><source>The EMBO Journal</source><volume>39</volume><elocation-id>e103695</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2019103695</pub-id><pub-id pub-id-type="pmid">32400009</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>WS</given-names></name><name><surname>Thompson</surname><given-names>MJ</given-names></name><name><surname>Taylor</surname><given-names>GA</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Promoter analysis of Zfp-36, the mitogen-inducible gene encoding the zinc finger protein tristetraprolin</article-title><source>The Journal of Biological Chemistry</source><volume>270</volume><fpage>25266</fpage><lpage>25272</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.42.25266</pub-id><pub-id pub-id-type="pmid">7559666</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>WS</given-names></name><name><surname>Carballo</surname><given-names>E</given-names></name><name><surname>Strum</surname><given-names>JR</given-names></name><name><surname>Kennington</surname><given-names>EA</given-names></name><name><surname>Phillips</surname><given-names>RS</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA</article-title><source>Molecular and Cellular Biology</source><volume>19</volume><fpage>4311</fpage><lpage>4323</lpage><pub-id pub-id-type="doi">10.1128/MCB.19.6.4311</pub-id><pub-id pub-id-type="pmid">10330172</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>WS</given-names></name><name><surname>Kennington</surname><given-names>EA</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Tristetraprolin and its family members can promote the cell-free deadenylation of AU-rich element-containing mRNAs by poly (a) ribonuclease</article-title><source>Molecular and Cellular Biology</source><volume>23</volume><fpage>3798</fpage><lpage>3812</lpage><pub-id pub-id-type="doi">10.1128/MCB.23.11.3798-3812.2003</pub-id><pub-id pub-id-type="pmid">12748283</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>WS</given-names></name><name><surname>Stumpo</surname><given-names>DJ</given-names></name><name><surname>Qiu</surname><given-names>L</given-names></name><name><surname>Faccio</surname><given-names>R</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A knock-in tristetraprolin (TTP) zinc finger point mutation in mice: comparison with complete TTP deficiency</article-title><source>Molecular and Cellular Biology</source><volume>38</volume><elocation-id>e00488-17</elocation-id><pub-id pub-id-type="doi">10.1128/MCB.00488-17</pub-id><pub-id pub-id-type="pmid">29203639</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>CW</given-names></name><name><surname>Corboy</surname><given-names>MJ</given-names></name><name><surname>DeMartino</surname><given-names>GN</given-names></name><name><surname>Thomas</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Endoproteolytic activity of the proteasome</article-title><source>Science</source><volume>299</volume><fpage>408</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1126/science.1079293</pub-id><pub-id pub-id-type="pmid">12481023</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>King</surname><given-names>RW</given-names></name><name><surname>Finley</surname><given-names>D</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Substrate degradation by the proteasome: a single-molecule kinetic analysis</article-title><source>Science</source><volume>348</volume><elocation-id>1250834</elocation-id><pub-id pub-id-type="doi">10.1126/science.1250834</pub-id><pub-id pub-id-type="pmid">25859050</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lykke-Andersen</surname><given-names>J</given-names></name><name><surname>Wagner</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Recruitment and activation of mRNA decay enzymes by two ARE-mediated decay activation domains in the proteins TTP and BRF-1</article-title><source>Genes &amp; Development</source><volume>19</volume><fpage>351</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1101/gad.1282305</pub-id><pub-id pub-id-type="pmid">15687258</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Madern</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Moritzmadern/cassiopeia_lfq: (V1.1)</data-title><version designator="V1.1">V1.1</version><source>Zenodo</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.5758975">https://doi.org/10.5281/zenodo.5758975</ext-link></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michlits</surname><given-names>G</given-names></name><name><surname>Jude</surname><given-names>J</given-names></name><name><surname>Hinterndorfer</surname><given-names>M</given-names></name><name><surname>de Almeida</surname><given-names>M</given-names></name><name><surname>Vainorius</surname><given-names>G</given-names></name><name><surname>Hubmann</surname><given-names>M</given-names></name><name><surname>Neumann</surname><given-names>T</given-names></name><name><surname>Schleiffer</surname><given-names>A</given-names></name><name><surname>Burkard</surname><given-names>TR</given-names></name><name><surname>Fellner</surname><given-names>M</given-names></name><name><surname>Gijsbertsen</surname><given-names>M</given-names></name><name><surname>Traunbauer</surname><given-names>A</given-names></name><name><surname>Zuber</surname><given-names>J</given-names></name><name><surname>Elling</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Multilayered VBC score predicts sgrnas that efficiently generate loss-of-function alleles</article-title><source>Nature Methods</source><volume>17</volume><fpage>708</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1038/s41592-020-0850-8</pub-id><pub-id pub-id-type="pmid">32514112</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ming</surname><given-names>XF</given-names></name><name><surname>Stoecklin</surname><given-names>G</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Looser</surname><given-names>R</given-names></name><name><surname>Moroni</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Parallel and independent regulation of interleukin-3 mrna turnover by phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>5778</fpage><lpage>5789</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.17.5778-5789.2001</pub-id><pub-id pub-id-type="pmid">11486017</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molle</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Ysebrant de Lendonck</surname><given-names>L</given-names></name><name><surname>Gueydan</surname><given-names>C</given-names></name><name><surname>Andrianne</surname><given-names>M</given-names></name><name><surname>Sherer</surname><given-names>F</given-names></name><name><surname>Van Simaeys</surname><given-names>G</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name><name><surname>Leo</surname><given-names>O</given-names></name><name><surname>Goriely</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Tristetraprolin regulation of interleukin 23 mrna stability prevents a spontaneous inflammatory disease</article-title><source>The Journal of Experimental Medicine</source><volume>210</volume><fpage>1675</fpage><lpage>1684</lpage><pub-id pub-id-type="doi">10.1084/jem.20120707</pub-id><pub-id pub-id-type="pmid">23940256</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Blachere</surname><given-names>NE</given-names></name><name><surname>Fak</surname><given-names>JJ</given-names></name><name><surname>Park</surname><given-names>CY</given-names></name><name><surname>Sawicka</surname><given-names>K</given-names></name><name><surname>Parveen</surname><given-names>S</given-names></name><name><surname>Zucker-Scharff</surname><given-names>I</given-names></name><name><surname>Moltedo</surname><given-names>B</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name><name><surname>Darnell</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ZFP36 RNA-binding proteins restrain T cell activation and anti-viral immunity</article-title><source>eLife</source><volume>7</volume><elocation-id>e33057</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.33057</pub-id><pub-id pub-id-type="pmid">29848443</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngoc</surname><given-names>LV</given-names></name><name><surname>Wauquier</surname><given-names>C</given-names></name><name><surname>Soin</surname><given-names>R</given-names></name><name><surname>Bousbata</surname><given-names>S</given-names></name><name><surname>Twyffels</surname><given-names>L</given-names></name><name><surname>Kruys</surname><given-names>V</given-names></name><name><surname>Gueydan</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Rapid proteasomal degradation of posttranscriptional regulators of the TIS11/tristetraprolin family is induced by an intrinsically unstructured region independently of ubiquitination</article-title><source>Molecular and Cellular Biology</source><volume>34</volume><fpage>4315</fpage><lpage>4328</lpage><pub-id pub-id-type="doi">10.1128/MCB.00643-14</pub-id><pub-id pub-id-type="pmid">25246635</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>AN</given-names></name><name><surname>Shiozaki</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Heat-shock-induced activation of stress MAP kinase is regulated by threonine- and tyrosine-specific phosphatases</article-title><source>Genes &amp; Development</source><volume>13</volume><fpage>1653</fpage><lpage>1663</lpage><pub-id pub-id-type="doi">10.1101/gad.13.13.1653</pub-id><pub-id pub-id-type="pmid">10398679</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platt</surname><given-names>RJ</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Yim</surname><given-names>MJ</given-names></name><name><surname>Swiech</surname><given-names>L</given-names></name><name><surname>Kempton</surname><given-names>HR</given-names></name><name><surname>Dahlman</surname><given-names>JE</given-names></name><name><surname>Parnas</surname><given-names>O</given-names></name><name><surname>Eisenhaure</surname><given-names>TM</given-names></name><name><surname>Jovanovic</surname><given-names>M</given-names></name><name><surname>Graham</surname><given-names>DB</given-names></name><name><surname>Jhunjhunwala</surname><given-names>S</given-names></name><name><surname>Heidenreich</surname><given-names>M</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Langer</surname><given-names>R</given-names></name><name><surname>Anderson</surname><given-names>DG</given-names></name><name><surname>Hacohen</surname><given-names>N</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Feng</surname><given-names>G</given-names></name><name><surname>Sharp</surname><given-names>PA</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CRISPR-cas9 knockin mice for genome editing and cancer modeling</article-title><source>Cell</source><volume>159</volume><fpage>440</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.09.014</pub-id><pub-id pub-id-type="pmid">25263330</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>ME</given-names></name><name><surname>Phipson</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Law</surname><given-names>CW</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Research</source><volume>43</volume><elocation-id>e47</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id><pub-id pub-id-type="pmid">25605792</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ronkina</surname><given-names>N</given-names></name><name><surname>Shushakova</surname><given-names>N</given-names></name><name><surname>Tiedje</surname><given-names>C</given-names></name><name><surname>Yakovleva</surname><given-names>T</given-names></name><name><surname>Tollenaere</surname><given-names>MAX</given-names></name><name><surname>Scott</surname><given-names>A</given-names></name><name><surname>Batth</surname><given-names>TS</given-names></name><name><surname>Olsen</surname><given-names>JV</given-names></name><name><surname>Helmke</surname><given-names>A</given-names></name><name><surname>Bekker-Jensen</surname><given-names>SH</given-names></name><name><surname>Clark</surname><given-names>AR</given-names></name><name><surname>Kotlyarov</surname><given-names>A</given-names></name><name><surname>Gaestel</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The role of TTP phosphorylation in the regulation of inflammatory cytokine production by MK2/3</article-title><source>Journal of Immunology</source><volume>203</volume><fpage>2291</fpage><lpage>2300</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1801221</pub-id><pub-id pub-id-type="pmid">31527197</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>EA</given-names></name><name><surname>Smallie</surname><given-names>T</given-names></name><name><surname>Ding</surname><given-names>Q</given-names></name><name><surname>O’Neil</surname><given-names>JD</given-names></name><name><surname>Cunliffe</surname><given-names>HE</given-names></name><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Rosner</surname><given-names>DR</given-names></name><name><surname>Klevernic</surname><given-names>I</given-names></name><name><surname>Morrice</surname><given-names>NA</given-names></name><name><surname>Monaco</surname><given-names>C</given-names></name><name><surname>Cunningham</surname><given-names>AF</given-names></name><name><surname>Buckley</surname><given-names>CD</given-names></name><name><surname>Saklatvala</surname><given-names>J</given-names></name><name><surname>Dean</surname><given-names>JL</given-names></name><name><surname>Clark</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dominant suppression of inflammation via targeted mutation of the mrna destabilizing protein tristetraprolin</article-title><source>Journal of Immunology</source><volume>195</volume><fpage>265</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1402826</pub-id><pub-id pub-id-type="pmid">26002976</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandler</surname><given-names>H</given-names></name><name><surname>Kreth</surname><given-names>J</given-names></name><name><surname>Timmers</surname><given-names>HThM</given-names></name><name><surname>Stoecklin</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Not1 mediates recruitment of the deadenylase caf1 to mrnas targeted for degradation by tristetraprolin</article-title><source>Nucleic Acids Research</source><volume>39</volume><fpage>4373</fpage><lpage>4386</lpage><pub-id pub-id-type="doi">10.1093/nar/gkr011</pub-id><pub-id pub-id-type="pmid">21278420</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauer</surname><given-names>I</given-names></name><name><surname>Schaljo</surname><given-names>B</given-names></name><name><surname>Vogl</surname><given-names>C</given-names></name><name><surname>Gattermeier</surname><given-names>I</given-names></name><name><surname>Kolbe</surname><given-names>T</given-names></name><name><surname>Müller</surname><given-names>M</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name><name><surname>Kovarik</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Interferons limit inflammatory responses by induction of tristetraprolin</article-title><source>Blood</source><volume>107</volume><fpage>4790</fpage><lpage>4797</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-07-3058</pub-id><pub-id pub-id-type="pmid">16514065</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaljo</surname><given-names>B</given-names></name><name><surname>Kratochvill</surname><given-names>F</given-names></name><name><surname>Gratz</surname><given-names>N</given-names></name><name><surname>Sadzak</surname><given-names>I</given-names></name><name><surname>Sauer</surname><given-names>I</given-names></name><name><surname>Hammer</surname><given-names>M</given-names></name><name><surname>Vogl</surname><given-names>C</given-names></name><name><surname>Strobl</surname><given-names>B</given-names></name><name><surname>Müller</surname><given-names>M</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name><name><surname>Poli</surname><given-names>V</given-names></name><name><surname>Lang</surname><given-names>R</given-names></name><name><surname>Murray</surname><given-names>PJ</given-names></name><name><surname>Kovarik</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Tristetraprolin is required for full anti-inflammatory response of murine macrophages to IL-10</article-title><source>Journal of Immunology</source><volume>183</volume><fpage>1197</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0803883</pub-id><pub-id pub-id-type="pmid">19542371</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schichl</surname><given-names>YM</given-names></name><name><surname>Resch</surname><given-names>U</given-names></name><name><surname>Lemberger</surname><given-names>CE</given-names></name><name><surname>Stichlberger</surname><given-names>D</given-names></name><name><surname>de Martin</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Novel phosphorylation-dependent ubiquitination of tristetraprolin by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1) and tumor necrosis factor receptor-associated factor 2 (TRAF2)</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><fpage>38466</fpage><lpage>38477</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.254888</pub-id><pub-id pub-id-type="pmid">21921033</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwanhäusser</surname><given-names>B</given-names></name><name><surname>Busse</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Dittmar</surname><given-names>G</given-names></name><name><surname>Schuchhardt</surname><given-names>J</given-names></name><name><surname>Wolf</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Selbach</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Global quantification of mammalian gene expression control</article-title><source>Nature</source><volume>473</volume><fpage>337</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1038/nature10098</pub-id><pub-id pub-id-type="pmid">21593866</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sedlyarov</surname><given-names>V</given-names></name><name><surname>Fallmann</surname><given-names>J</given-names></name><name><surname>Ebner</surname><given-names>F</given-names></name><name><surname>Huemer</surname><given-names>J</given-names></name><name><surname>Sneezum</surname><given-names>L</given-names></name><name><surname>Ivin</surname><given-names>M</given-names></name><name><surname>Kreiner</surname><given-names>K</given-names></name><name><surname>Tanzer</surname><given-names>A</given-names></name><name><surname>Vogl</surname><given-names>C</given-names></name><name><surname>Hofacker</surname><given-names>I</given-names></name><name><surname>Kovarik</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tristetraprolin binding site atlas in the macrophage transcriptome reveals a switch for inflammation resolution</article-title><source>Molecular Systems Biology</source><volume>12</volume><elocation-id>868</elocation-id><pub-id pub-id-type="doi">10.15252/msb.20156628</pub-id><pub-id pub-id-type="pmid">27178967</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Linear models and empirical Bayes methods for assessing differential expression in microarray experiments</article-title><source>Statistical Applications in Genetics and Molecular Biology</source><volume>3</volume><fpage>1</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.2202/1544-6115.1027</pub-id><pub-id pub-id-type="pmid">16646809</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sneezum</surname><given-names>L</given-names></name><name><surname>Eislmayr</surname><given-names>K</given-names></name><name><surname>Dworak</surname><given-names>H</given-names></name><name><surname>Sedlyarov</surname><given-names>V</given-names></name><name><surname>Le Heron</surname><given-names>A</given-names></name><name><surname>Ebner</surname><given-names>F</given-names></name><name><surname>Fischer</surname><given-names>I</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><name><surname>Kovarik</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Context-Dependent IL-1 mRNA-destabilization by TTP prevents dysregulation of immune homeostasis under steady state conditions</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>1398</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.01398</pub-id><pub-id pub-id-type="pmid">32733464</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Senevirathne</surname><given-names>C</given-names></name><name><surname>Aluri</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Xavier-Ferrucio</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>S</given-names></name><name><surname>Tran</surname><given-names>NT</given-names></name><name><surname>Liu</surname><given-names>SM</given-names></name><name><surname>Sun</surname><given-names>CW</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Cable</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Qu</surname><given-names>CK</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Klug</surname><given-names>CA</given-names></name><name><surname>Bhatia</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Nimer</surname><given-names>SD</given-names></name><name><surname>Zheng</surname><given-names>YG</given-names></name><name><surname>Iancu-Rubin</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>H</given-names></name><name><surname>Krause</surname><given-names>DS</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Methylation of dual-specificity phosphatase 4 controls cell differentiation</article-title><source>Cell Reports</source><volume>36</volume><elocation-id>109421</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109421</pub-id><pub-id pub-id-type="pmid">34320342</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><name><surname>Ikeda</surname><given-names>K</given-names></name><name><surname>Maezawa</surname><given-names>Y</given-names></name><name><surname>Suto</surname><given-names>A</given-names></name><name><surname>Takatori</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Iwamoto</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>IL-4-stat6 signaling induces tristetraprolin expression and inhibits TNF-alpha production in mast cells</article-title><source>The Journal of Experimental Medicine</source><volume>198</volume><fpage>1717</fpage><lpage>1727</lpage><pub-id pub-id-type="doi">10.1084/jem.20031701</pub-id><pub-id pub-id-type="pmid">14638848</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takekawa</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Protein phosphatase 2Calpha inhibits the human stress-responsive p38 and JNK MAPK pathways</article-title><source>The EMBO Journal</source><volume>17</volume><fpage>4744</fpage><lpage>4752</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.16.4744</pub-id><pub-id pub-id-type="pmid">9707433</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takekawa</surname><given-names>M</given-names></name><name><surname>Adachi</surname><given-names>M</given-names></name><name><surname>Nakahata</surname><given-names>A</given-names></name><name><surname>Nakayama</surname><given-names>I</given-names></name><name><surname>Itoh</surname><given-names>F</given-names></name><name><surname>Tsukuda</surname><given-names>H</given-names></name><name><surname>Taya</surname><given-names>Y</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>P53-Inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-P53 signaling in response to UV radiation</article-title><source>The EMBO Journal</source><volume>19</volume><fpage>6517</fpage><lpage>6526</lpage><pub-id pub-id-type="doi">10.1093/emboj/19.23.6517</pub-id><pub-id pub-id-type="pmid">11101524</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taus</surname><given-names>T</given-names></name><name><surname>Köcher</surname><given-names>T</given-names></name><name><surname>Pichler</surname><given-names>P</given-names></name><name><surname>Paschke</surname><given-names>C</given-names></name><name><surname>Schmidt</surname><given-names>A</given-names></name><name><surname>Henrich</surname><given-names>C</given-names></name><name><surname>Mechtler</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Universal and confident phosphorylation site localization using phosphors</article-title><source>Journal of Proteome Research</source><volume>10</volume><fpage>5354</fpage><lpage>5362</lpage><pub-id pub-id-type="doi">10.1021/pr200611n</pub-id><pub-id pub-id-type="pmid">22073976</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>GA</given-names></name><name><surname>Carballo</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>DM</given-names></name><name><surname>Lai</surname><given-names>WS</given-names></name><name><surname>Thompson</surname><given-names>MJ</given-names></name><name><surname>Patel</surname><given-names>DD</given-names></name><name><surname>Schenkman</surname><given-names>DI</given-names></name><name><surname>Gilkeson</surname><given-names>GS</given-names></name><name><surname>Broxmeyer</surname><given-names>HE</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency</article-title><source>Immunity</source><volume>4</volume><fpage>445</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(00)80411-2</pub-id><pub-id pub-id-type="pmid">8630730</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>JW</given-names></name><name><surname>Nagel</surname><given-names>J</given-names></name><name><surname>Hoving</surname><given-names>S</given-names></name><name><surname>Gerrits</surname><given-names>B</given-names></name><name><surname>Bauer</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>JR</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name><name><surname>Schirle</surname><given-names>M</given-names></name><name><surname>Luchansky</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Quantitative Lys-ϵ-Gly-Gly (diGly) proteomics coupled with inducible RNAi reveals ubiquitin-mediated proteolysis of DNA damage-inducible transcript 4 (DDIT4) by the E3 ligase HUWE1</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>28942</fpage><lpage>28955</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.573352</pub-id><pub-id pub-id-type="pmid">25147182</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiedje</surname><given-names>C</given-names></name><name><surname>Diaz-Muñoz</surname><given-names>MD</given-names></name><name><surname>Trulley</surname><given-names>P</given-names></name><name><surname>Ahlfors</surname><given-names>H</given-names></name><name><surname>Laaß</surname><given-names>K</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name><name><surname>Turner</surname><given-names>M</given-names></name><name><surname>Gaestel</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The RNA-binding protein TTP is a global post-transcriptional regulator of feedback control in inflammation</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>7418</fpage><lpage>7440</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw474</pub-id><pub-id pub-id-type="pmid">27220464</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Lee</surname><given-names>R</given-names></name><name><surname>Lang</surname><given-names>B</given-names></name><name><surname>Kruse</surname><given-names>K</given-names></name><name><surname>Gsponer</surname><given-names>J</given-names></name><name><surname>Sánchez de Groot</surname><given-names>N</given-names></name><name><surname>Huynen</surname><given-names>MA</given-names></name><name><surname>Matouschek</surname><given-names>A</given-names></name><name><surname>Fuxreiter</surname><given-names>M</given-names></name><name><surname>Babu</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Intrinsically disordered segments affect protein half-life in the cell and during evolution</article-title><source>Cell Reports</source><volume>8</volume><fpage>1832</fpage><lpage>1844</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.07.055</pub-id><pub-id pub-id-type="pmid">25220455</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warmka</surname><given-names>J</given-names></name><name><surname>Hanneman</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Amin</surname><given-names>D</given-names></name><name><surname>Ota</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Ptc1, a type 2C Ser/Thr phosphatase, inactivates the hog pathway by dephosphorylating the mitogen-activated protein kinase Hog1</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.1.51-60.2001</pub-id><pub-id pub-id-type="pmid">11113180</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Anderson</surname><given-names>DE</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The HECT domain ubiquitin ligase HUWE1 targets unassembled soluble proteins for degradation</article-title><source>Cell Discovery</source><volume>2</volume><elocation-id>16040</elocation-id><pub-id pub-id-type="doi">10.1038/celldisc.2016.40</pub-id><pub-id pub-id-type="pmid">27867533</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yee</surname><given-names>JK</given-names></name><name><surname>Friedmann</surname><given-names>T</given-names></name><name><surname>Burns</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Generation of high-titer pseudotyped retroviral vectors with very broad host range</article-title><source>Methods in Cell Biology</source><volume>43</volume><fpage>99</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/s0091-679x(08)60600-7</pub-id><pub-id pub-id-type="pmid">7823872</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Translation repression via modulation of the cytoplasmic poly (a) -binding protein in the inflammatory response</article-title><source>eLife</source><volume>6</volume><elocation-id>e27786</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.27786</pub-id><pub-id pub-id-type="pmid">28635594</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83159.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Xiaoyu</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cve4549</institution-id><institution>Tsinghua University</institution></institution-wrap><country>China</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.08.29.505645" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.08.29.505645"/></front-stub><body><p>The study by Scinicariello et al. set out to identify novel factors that controlled TTP stability and identified HUWE1 by CRISPR screening in macrophages. HUWE1 limited TTP phosphorylation at later times post inflammatory stimulation on residues distinct from those functionally modified by MAPKs in early stages. Overall, the biochemical and cellular signaling experiments were thoughtfully designed and well executed, leading to the discovery of HUWE1 as a TTP regulator.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83159.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Hu</surname><given-names>Xiaoyu</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cve4549</institution-id><institution>Tsinghua University</institution></institution-wrap><country>China</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.08.29.505645">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.08.29.505645v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;HUWE1 controls tristetraprolin proteasomal degradation by regulating its phosphorylation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by David Ron as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>Please experimentally address the questions raised by the reviewers.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The study by Scinicariello et al. set out to identify novel factors that controlled TTP stability and identified HUWE1 by CRISPR screening in macrophages. HUWE1 phosphorylated TTP on residues distinct from those phosphorylated by MAPKs and regulated TTP protein stability. Overall, the biochemical and cellular signaling experiments were thoughtfully designed and well executed, leading to the discovery of HUWE1 as a TTP regulator. Addressing the following questions may help strengthen the conclusion that HUWE1 regulates macrophage responses at the post-transcriptional steps.</p><p>1. In Figure 3B, the authors showed that HUWE1-deficient BMDMs expressed reduced levels of Il6 mRNA upon LPS stimulation. It would be desirable for the authors to assess the levels of Il6 primary transcripts, a proxy of Il6 gene transcription, to exclude the possibility that HUWE1 affected mRNA synthesis instead of TTP-mediated degradation.</p><p>2. It would also be desirable to measure protein levels of prototypical inflammatory cytokines in HUWE1-deficient BMDMs to ascertain the effects of HUWE1 on inflammatory outcomes.</p><p>3. For some reason, the resolution of Figure 7 is low such that the model could not be properly visualized and interpreted.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Sara Scinicariello et al., found that ubiquitin E3 ligase HUWE1 regulated proteasomal degradation of TTP by regulating its phosphorylation. Their conclusions are supported by biochemistry experiments. However, the physiological importance of the process was not investigated here. Moreover, the accurate mechanism by which HUWE1 regulated the phosphorylation of TTP was not clarified.</p><p>Specific points:</p><p>1. Authors indicated that LPS-induced TPP hyperphosphorylation in Figure 1B and 1G, but the result in Figure 1F was not as significant as in Figure 1B and 1G.</p><p>2. In Figure 2C, the expression of Endogenic TPP was up-regulated after LPS stimulation, but the expression of mCherry TTP was down-regulated. Contradiction with the trend mentioned by the author in Figure 1E.</p><p>3. The image of all figures' quality and resolution is very low, and it is difficult to read and understand.</p><p>4. Line 209: &quot;either result in increased intracellular TTP protein concentrations &quot;. This sentence looks redundant with &quot;increased TTP protein levels upon Huwe1 ablation&quot;</p><p>5. In figure 3, the author examined the induction of IL6 and TNF. As the experiments were performed in WT and HUWE1 KO (or KD) cell lines. It is possible that HUWE1 might regulate the induction of these cytokines. Control should be added before drawing a conclusion. For example, reconstitute TTP into HUWE1 KO (or KD) cell line.</p><p>6. Line 237~238: It is weird that the association between TTP and HUWE1 was not detected with co-IP or turbo-ID assay. As turbo-ID was able to detect weak and transient interaction.</p><p>7. Line 316: In figure 4E, Since both sets have no significant difference between control and Huwe1 KO, it is not proper to conclude a &quot;rescue&quot;, especially with nearly the same error bar.</p><p>8. The authors should identify the exact AA sites where HUWE1 affects TTP ubiquitination and phosphorylation and performed mutation validation.</p><p>9. AA 234-258 are almost all phosphorylated regions of TTP (Figure 6C), deletion of the 234-258 region of TTP fails to hyperphosphorylate in HUWE1 knockout cells and cannot be proved to be the effect of HEWE1.</p><p>10. HUWE1 acts as an E3 ubiquitin ligase and has no interaction with TTP. How HUWE1 affects the ubiquitination and phosphorylation of TTP. The author should explain this.</p><p>11. The authors did not provide enough evidence to support that HUWE1 phosphorylates TTP via PP1/2.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Figure 1A: Mg132 treatment reveals proteasome-dependent degradation of endogenous TTP. Sensitivity to TAK243 should also be assessed to determine whether, as observed with the overexpressed TTP-HA protein, endogenous TTP degradation is sensitive to ubiquitination inhibitors.</p><p>Similarly, the claim that TTP is degraded in a ubiquitin-dependent manner (see the title of Figure 1) should be supported by data demonstrating that endogenous TTP protein is modified by ubiquitination. This could be achieved by an experiment similar to that shown in 1C performed by immunoprecipitation of endogenous TTP protein. Alternatively, a new approach to identify endogenous ubiquitination could be tested (see for example Zhang et al. PLOS Biology 2022 20:e3001501).</p><p>Sup. Figure 1B: Half-lifes of TTP wt and TTP K→R mutant should be compared by measuring the decrease in protein level after translational blockade (as performed in Figure 1A and 2G) to convincingly demonstrate that the absence of ubiquitination is correlated with the stabilization of TTP.</p><p>Figure 1E: In order to demonstrate a specific variation of mCherry-TTP level in response to LPS (similar to what is observed for the endogenous TTP protein), the level of mCherry-TTP measured in experiment 1E should be expressed relative to the level of eBFP. This would normalize potential variations in lentiviral promoter activity under the effect of LPS treatment.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83159.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. In Figure 3B, the authors showed that HUWE1-deficient BMDMs expressed reduced levels of Il6 mRNA upon LPS stimulation. It would be desirable for the authors to assess the levels of Il6 primary transcripts, a proxy of Il6 gene transcription, to exclude the possibility that HUWE1 affected mRNA synthesis instead of TTP-mediated degradation.</p></disp-quote><p>To determine whether <italic>Huwe1</italic> knock-out influences TTP-target mRNAs at a posttranscriptional level, we analyzed the mature and pre-mRNA levels of one of TTP’s bestcharacterized targets -<italic>Tnf-</italic> by RT-qPCR using exon-exon, and intron-exon primer pairs, respectively. These new data have been added as Figure 3A and 3B in the revised manuscript.</p><p>Consistent with the effects of <italic>Huwe1</italic>-loss on TTP-regulated mRNAs stemming from post-transcriptional effects, <italic>Tnf</italic> pre-mRNA levels were unaffected in <italic>Huwe1</italic> KO cells, whereas its mature mRNA was decreased (consistent with increased intra-cellular levels of biologically active TTP protein).</p><disp-quote content-type="editor-comment"><p>2. It would also be desirable to measure protein levels of prototypical inflammatory cytokines in HUWE1-deficient BMDMs to ascertain the effects of HUWE1 on inflammatory outcomes.</p></disp-quote><p>To determine whether differences in mRNA levels in <italic>Huwe1</italic> KO cells are reflected at the protein level, intra-cellular TNF protein abundance was determined by flow-cytometry. New data have been added as Figure 3 —figure supplement 1F in the revised manuscript.</p><p>Consistent with our <italic>Tnf</italic> mRNA data, there were no significant changes in intra-cellular TNF protein <italic>HUWE1</italic> KO cells at 3 h post LPS stimulation. However, as is the case for its mRNA, at later time points post-stimulation (6, and 9 h), TNF protein was significantly reduced in the absence of <italic>Huwe1</italic>.</p><disp-quote content-type="editor-comment"><p>3. For some reason, the resolution of Figure 7 is low such that the model could not be properly visualized and interpreted.</p></disp-quote><p>This likely happened during PDF conversion of the original manuscript. The revised PDF manuscript figures, and uploaded individual figures should be high resolution now, and allow for proper evaluation.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Sara Scinicariello et al., found that ubiquitin E3 ligase HUWE1 regulated proteasomal degradation of TTP by regulating its phosphorylation. Their conclusions are supported by biochemistry experiments. However, the physiological importance of the process was not investigated here. Moreover, the accurate mechanism by which HUWE1 regulated the phosphorylation of TTP was not clarified.</p><p>Specific points:</p><p>1. Authors indicated that LPS-induced TPP hyperphosphorylation in Figure 1B and 1G, but the result in Figure 1F was not as significant as in Figure 1B and 1G.</p></disp-quote><p>We acknowledge that there are some minor differences in the magnitude of phosphorylation, and phosphorylation timing/kinetics between mCherry-TTP, HA-TTP, and endogenous TTP. Nevertheless, in all cases, all constructs in all tested cell types behaved conceptually in a similar manner. Specifically, we interpreted endogenous TTP to be substantially phosphorylated upon LPS treatment in Figure 1F, as phosphatase treatment collapsed the higher MW TTP species. The same was the case for mCherry-TTP upon phosphatase treatment. The increase in mCherry-TTP MW through LPS treatment is less pronounced on the blot, which we interpreted to stem from the more limited size-resolution higher up in the SDS-PAGE gel.</p><disp-quote content-type="editor-comment"><p>2. In Figure 2C, the expression of Endogenic TPP was up-regulated after LPS stimulation, but the expression of mCherry TTP was down-regulated. Contradiction with the trend mentioned by the author in Figure 1E.</p></disp-quote><p>We do not think that the data from these two panels in contradictory. The data presented in Figure 1E show that mCherry-TTP is stabilized at earlier times post-LPS stimulation (peak at 3 h), yet decreased below the initial steady-state levels by 6 h post-LPS stimulation. Collectively, our data suggest that this behavior stems from initial LPS-induced TTP stabilization (at 3 h), followed by LPS-dependent TTP degradation (≥6 h).</p><p>In order to measure the effect of <italic>Huwe1</italic>-loss on TTP degradation, the experiment in Figure 2C was performed at 6 h post-LPS stimulation; i.e. at a time during which mCherry-TTP is already lower than its initial steady-state levels in the sg<italic>ROSA</italic>+LPS control samples. Therefore, our conclusion is that the results in Figure 1E and 2C are in fact consistent.</p><disp-quote content-type="editor-comment"><p>3. The image of all figures' quality and resolution is very low, and it is difficult to read and understand.</p></disp-quote><p>This likely happened during PDF conversion of the original manuscript. The revised PDF manuscript figures, and uploaded individual figures should be high resolution now, and allow for proper evaluation.</p><disp-quote content-type="editor-comment"><p>4. Line 209: &quot;either result in increased intracellular TTP protein concentrations &quot;. This sentence looks redundant with &quot;increased TTP protein levels upon Huwe1 ablation&quot;</p></disp-quote><p>We agree, and have adapted the revised manuscript text by removing “result in increased intracellular TTP protein concentrations, and”.</p><disp-quote content-type="editor-comment"><p>5. In figure 3, the author examined the induction of IL6 and TNF. As the experiments were performed in WT and HUWE1 KO (or KD) cell lines. It is possible that HUWE1 might regulate the induction of these cytokines. Control should be added before drawing a conclusion. For example, reconstitute TTP into HUWE1 KO (or KD) cell line.</p></disp-quote><p>To determine whether <italic>Huwe1</italic> knock-out influences TTP-target mRNAs at a posttranscriptional level, we analyzed the mature and pre-mRNA levels of one of TTP’s bestcharacterized targets -<italic>Tnf-</italic> by RT-qPCR using exon-exon, and intron-exon primer pairs, respectively. These new data have been added as Figure 3A and 3B in the revised manuscript.</p><p>Consistent with the effects of <italic>Huwe1</italic>-loss on TTP-regulated mRNAs stemming from post-transcriptional effects, <italic>Tnf</italic> pre-mRNA levels were unaffected in <italic>Huwe1</italic> KO cells, whereas its mature mRNA was decreased (consistent with increased intra-cellular levels of biologically active TTP protein).</p><disp-quote content-type="editor-comment"><p>6. Line 237~238: It is weird that the association between TTP and HUWE1 was not detected with co-IP or turbo-ID assay. As turbo-ID was able to detect weak and transient interaction.</p></disp-quote><p>We concluded from these results that there are two possible explanations: (1) TTP is a direct substrate for HUWE1, resulting in its poly-ubiquitination and degradation, but the HUWE1-TTP interaction in cells is too weak to measure even by TurboID, or (2) HUWE1 affects TTP stability indirectly, e.g. by altering its phosphorylation.</p><p>Our data cannot exclude option 1 to be true (i.e. that HUWE1 ubiquitinates TTP). However, irrespective of whether option 1 is true, data presented in Figure 4 indicate that HUWE1 (also) affects TTP stability indirectly, by regulating its phosphorylation. Text in lines 249-259 of the revised manuscript addresses these points.</p><disp-quote content-type="editor-comment"><p>7. Line 316: In figure 4E, Since both sets have no significant difference between control and Huwe1 KO, it is not proper to conclude a &quot;rescue&quot;, especially with nearly the same error bar.</p></disp-quote><p>We agree, and updated the text in the revised manuscript (lines 329-336).</p><disp-quote content-type="editor-comment"><p>8. The authors should identify the exact AA sites where HUWE1 affects TTP ubiquitination and phosphorylation and performed mutation validation.</p></disp-quote><p>The strong hyper-phosphorylation of TTP in the absence of HUWE1 indicates that many sites on TTP are (de)phosphorylated in a HUWE1-dependent manner, and thus likely contribute to regulation of TTP turnover. We aim to systematically test the contribution of each phospho-site to TTP stability regulation in the future, yet are of the opinion that this is not essential to the claims made in the current manuscript.</p><p>Moreover, we performed additional single and combinatorial KtoR mutagenesis. New data from the single mutants was added as Figure 1 —figure supplement 1F. TTP became fully stable only when all five lysine residues were muted (as shown in the original manuscript). This indicates that multiple lysine residues are ubiquitinated, and that single mutants can be compensated for by the other residues. This is not uncommon for many E3s, which have the structural flexibility to ubiquitinate any residues in particular substrate surfaces.</p><p>Our data indicate that HUWE1-related phosphorylation and ubiquitination events occur on multiple sites in TTP, and are functionally redundant/complementary.</p><disp-quote content-type="editor-comment"><p>9. AA 234-258 are almost all phosphorylated regions of TTP (Figure 6C), deletion of the 234-258 region of TTP fails to hyperphosphorylate in HUWE1 knockout cells and cannot be proved to be the effect of HEWE1.</p></disp-quote><p>Since the 234-258 region is not presented in Figure 6C, we assumed that Figure 6E was meant instead. Moreover, it is not clear to us exactly what the reviewer meant here, as deletion of the 234-258 region resulted in more TTP phosphorylation in sg<italic>AAVS1</italic> control cells (Figure 6E, and Figure 6 —figure supplement 1G), and this was not affected by <italic>Huwe1</italic> KO.</p><p>Nevertheless, from Figure 6E we concluded that the 234-258 is a likely binding site for the TTP phosphatase. We interpreted these data as follows: (1) in the absence of phosphatase binding (i.e. 234-258 deletion), TTP is hyper-phosphorylated, and (2) since <italic>Huwe1</italic> KO no longer increased TTP abundance of this mutant, the effect of HUWE1 on wild-type TTP occurs -at least in part- through differential TTP phosphorylation.</p><disp-quote content-type="editor-comment"><p>10. HUWE1 acts as an E3 ubiquitin ligase and has no interaction with TTP. How HUWE1 affects the ubiquitination and phosphorylation of TTP. The author should explain this.</p></disp-quote><p>This is discussed in detail in revised manuscript lines 468-479 (Results section) and 569-581 (Discussion section), and illustrated in Figure 7.</p><disp-quote content-type="editor-comment"><p>11. The authors did not provide enough evidence to support that HUWE1 phosphorylates TTP via PP1/2.</p></disp-quote><p>In our opinion, we do not make any strong claims in the manuscript that HUWE1 regulates PP1/2, rather indicate that aberrant PP1/2 activity would offer a reasonable explanation for the <italic>Huwe1</italic> KO phenotype.</p><p>In our opinion, the data presented in Figures 4E-F demonstrate with two independent sets of inhibitors, that prevent either phosphorylation, or dephosphorylation have the same effect: it negates the increase in TTP abundance caused by loss of <italic>Huwe1</italic>. Our main conclusion from this is, that the <italic>Huwe1</italic> KO phenotype is dependent on TTP phosphorylation, and that either preventing TTP phosphorylation (4i), or saturating it (CalycA), renders TTP insensitive to <italic>Huwe1</italic> loss.</p><p>Based on (1) aberrant activation of multiple stress kinases (Figure 4A-D), (2) these inhibitor experiments in Figure 4E-F, and (3) independent mutagenesis experiments in Figure 6, we <italic>suggest</italic> that the HUWE1-dependent effects on TTP <italic>may</italic> be through PP1/2. We are aiming to address this in more detail in future experiments, outside of the scope of this manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Figure 1A: Mg132 treatment reveals proteasome-dependent degradation of endogenous TTP. Sensitivity to TAK243 should also be assessed to determine whether, as observed with the overexpressed TTP-HA protein, endogenous TTP degradation is sensitive to ubiquitination inhibitors.</p></disp-quote><p>New data assessing the effect of TAK-243 on endogenous TTP was added as Figure 1 —figure supplement 1B. Consistent with our data with exogenously expressed TTP, treatment with the inhibitor increased the abundance of endogenous TTP.</p><disp-quote content-type="editor-comment"><p>Similarly, the claim that TTP is degraded in a ubiquitin-dependent manner (see the title of Figure 1) should be supported by data demonstrating that endogenous TTP protein is modified by ubiquitination. This could be achieved by an experiment similar to that shown in 1C performed by immunoprecipitation of endogenous TTP protein. Alternatively, a new approach to identify endogenous ubiquitination could be tested (see for example Zhang et al. PLOS Biology 2022 20:e3001501).</p></disp-quote><p>New data assessing the ubiquitination of endogenous TTP was added as Figure 1 —figure supplement 1D.</p><disp-quote content-type="editor-comment"><p>Sup. Figure 1B: Half-lifes of TTP wt and TTP K→R mutant should be compared by measuring the decrease in protein level after translational blockade (as performed in Figure 1A and 2G) to convincingly demonstrate that the absence of ubiquitination is correlated with the stabilization of TTP.</p></disp-quote><p>New data from TTP-KtoR chase experiments was added as Figure 1 —figure supplement 1E. The half-life was increased substantially from 1.4 h for wtTTP to 5.7 h for the mutant.</p><disp-quote content-type="editor-comment"><p>Figure 1E: In order to demonstrate a specific variation of mCherry-TTP level in response to LPS (similar to what is observed for the endogenous TTP protein), the level of mCherry-TTP measured in experiment 1E should be expressed relative to the level of eBFP. This would normalize potential variations in lentiviral promoter activity under the effect of LPS treatment.</p></disp-quote><p>All of our FACS-based experiments with the mCherry-TTP-P2A-eBFP2 cells (e.g. Figure 2 —figure supplement 2E) have consistently demonstrated that BFP levels are not affected by <italic>Huwe1</italic> KO. Since the data from Figure 1E come from Western blot analyses, BFP values were not measured, and could not be used for normalization.</p></body></sub-article></article>